EP1561114B1 - Fret probes and methods for detecting interacting molecules - Google Patents
Fret probes and methods for detecting interacting molecules Download PDFInfo
- Publication number
- EP1561114B1 EP1561114B1 EP03776064A EP03776064A EP1561114B1 EP 1561114 B1 EP1561114 B1 EP 1561114B1 EP 03776064 A EP03776064 A EP 03776064A EP 03776064 A EP03776064 A EP 03776064A EP 1561114 B1 EP1561114 B1 EP 1561114B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- probe
- probes
- binding
- dyes
- reactive group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000523 sample Substances 0.000 title claims abstract description 279
- 238000000034 method Methods 0.000 title claims abstract description 63
- 238000012546 transfer Methods 0.000 claims abstract description 45
- 239000000975 dye Substances 0.000 claims description 111
- 238000002866 fluorescence resonance energy transfer Methods 0.000 claims description 63
- 230000027455 binding Effects 0.000 claims description 52
- 230000003993 interaction Effects 0.000 claims description 50
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 42
- 238000001514 detection method Methods 0.000 claims description 32
- 239000000126 substance Substances 0.000 claims description 29
- 150000001875 compounds Chemical class 0.000 claims description 24
- 229960002685 biotin Drugs 0.000 claims description 21
- 235000020958 biotin Nutrition 0.000 claims description 21
- 239000011616 biotin Substances 0.000 claims description 21
- 150000002632 lipids Chemical class 0.000 claims description 18
- 150000007523 nucleic acids Chemical class 0.000 claims description 16
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 108090001008 Avidin Proteins 0.000 claims description 12
- 238000000684 flow cytometry Methods 0.000 claims description 12
- 239000002771 cell marker Substances 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims description 8
- 239000003068 molecular probe Substances 0.000 claims description 8
- 150000001720 carbohydrates Chemical class 0.000 claims description 7
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 claims description 7
- 238000010186 staining Methods 0.000 claims description 7
- 108010004469 allophycocyanin Proteins 0.000 claims description 6
- OBYNJKLOYWCXEP-UHFFFAOYSA-N 2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]-4-isothiocyanatobenzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(N=C=S)=CC=C1C([O-])=O OBYNJKLOYWCXEP-UHFFFAOYSA-N 0.000 claims description 5
- 108010090804 Streptavidin Proteins 0.000 claims description 5
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 3
- 108060006184 phycobiliprotein Proteins 0.000 claims description 3
- 230000009870 specific binding Effects 0.000 claims description 3
- 239000012099 Alexa Fluor family Substances 0.000 claims description 2
- 230000004069 differentiation Effects 0.000 claims description 2
- 239000002096 quantum dot Substances 0.000 claims description 2
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 claims description 2
- 238000009007 Diagnostic Kit Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 82
- 210000004027 cell Anatomy 0.000 description 80
- 102000004169 proteins and genes Human genes 0.000 description 76
- 235000018102 proteins Nutrition 0.000 description 75
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- 102000053602 DNA Human genes 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 13
- 238000002372 labelling Methods 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 11
- 230000008045 co-localization Effects 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 230000021615 conjugation Effects 0.000 description 9
- 230000003834 intracellular effect Effects 0.000 description 9
- 239000003446 ligand Substances 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 230000002159 abnormal effect Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 230000008520 organization Effects 0.000 description 7
- 230000011664 signaling Effects 0.000 description 7
- 108010042653 IgA receptor Proteins 0.000 description 6
- 102100034014 Prolyl 3-hydroxylase 3 Human genes 0.000 description 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 6
- 150000003141 primary amines Chemical class 0.000 description 6
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 5
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 5
- 108091093037 Peptide nucleic acid Proteins 0.000 description 5
- 108091008874 T cell receptors Proteins 0.000 description 5
- 239000012491 analyte Substances 0.000 description 5
- 239000012472 biological sample Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000005284 excitation Effects 0.000 description 5
- 239000007850 fluorescent dye Substances 0.000 description 5
- 239000005090 green fluorescent protein Substances 0.000 description 5
- 230000004001 molecular interaction Effects 0.000 description 5
- 239000002853 nucleic acid probe Substances 0.000 description 5
- 229920002477 rna polymer Polymers 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 102000001301 EGF receptor Human genes 0.000 description 4
- 108060006698 EGF receptor Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102000003945 NF-kappa B Human genes 0.000 description 4
- 108010057466 NF-kappa B Proteins 0.000 description 4
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000003915 cell function Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachlorophenol Chemical compound OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000006916 protein interaction Effects 0.000 description 4
- 230000004850 protein–protein interaction Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 101000716124 Homo sapiens T-cell surface glycoprotein CD1c Proteins 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 150000001982 diacylglycerols Chemical class 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- -1 glycoconjugates Proteins 0.000 description 3
- 108010044426 integrins Proteins 0.000 description 3
- 102000006495 integrins Human genes 0.000 description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108010038196 saccharide-binding proteins Proteins 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 230000003335 steric effect Effects 0.000 description 3
- 101710159080 Aconitate hydratase A Proteins 0.000 description 2
- 101710159078 Aconitate hydratase B Proteins 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- 108060000903 Beta-catenin Proteins 0.000 description 2
- 102000015735 Beta-catenin Human genes 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 108010009306 Forkhead Box Protein O1 Proteins 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000003729 Neprilysin Human genes 0.000 description 2
- 108090000028 Neprilysin Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 229920000388 Polyphosphate Polymers 0.000 description 2
- 108091008611 Protein Kinase B Proteins 0.000 description 2
- 108090000315 Protein Kinase C Proteins 0.000 description 2
- 102000003923 Protein Kinase C Human genes 0.000 description 2
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 description 2
- 102000001183 RAG-1 Human genes 0.000 description 2
- 108060006897 RAG1 Proteins 0.000 description 2
- 102000015097 RNA Splicing Factors Human genes 0.000 description 2
- 108010039259 RNA Splicing Factors Proteins 0.000 description 2
- 101710105008 RNA-binding protein Proteins 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 102000036646 Signalosomes Human genes 0.000 description 2
- 108091007411 Signalosomes Proteins 0.000 description 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000006287 biotinylation Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 102000023852 carbohydrate binding proteins Human genes 0.000 description 2
- 125000000837 carbohydrate group Chemical group 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000834 fixative Substances 0.000 description 2
- 238000002292 fluorescence lifetime imaging microscopy Methods 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 108091006050 fluorescent recombinant proteins Proteins 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000004524 haematopoietic cell Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000009878 intermolecular interaction Effects 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 230000004576 lipid-binding Effects 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 230000008823 permeabilization Effects 0.000 description 2
- XEBWQGVWTUSTLN-UHFFFAOYSA-M phenylmercury acetate Chemical compound CC(=O)O[Hg]C1=CC=CC=C1 XEBWQGVWTUSTLN-UHFFFAOYSA-M 0.000 description 2
- 150000003906 phosphoinositides Chemical class 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000001205 polyphosphate Substances 0.000 description 2
- 235000011176 polyphosphates Nutrition 0.000 description 2
- 230000009822 protein phosphorylation Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 2
- YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical class C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- BPVHBBXCESDRKW-UHFFFAOYSA-N 5(6)-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21.C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BPVHBBXCESDRKW-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 241000242764 Aequorea victoria Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000003930 C-Type Lectins Human genes 0.000 description 1
- 108090000342 C-Type Lectins Proteins 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- 102000010831 Cytoskeletal Proteins Human genes 0.000 description 1
- 108010037414 Cytoskeletal Proteins Proteins 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 102100029951 Estrogen receptor beta Human genes 0.000 description 1
- 102100035427 Forkhead box protein O1 Human genes 0.000 description 1
- 102000007563 Galectins Human genes 0.000 description 1
- 108010046569 Galectins Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101000980827 Homo sapiens T-cell surface glycoprotein CD1a Proteins 0.000 description 1
- 101000716149 Homo sapiens T-cell surface glycoprotein CD1b Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 101001061851 Homo sapiens V(D)J recombination-activating protein 2 Proteins 0.000 description 1
- 102100032818 Integrin alpha-4 Human genes 0.000 description 1
- 102100025304 Integrin beta-1 Human genes 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108010010522 Phycobilisomes Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 102000001788 Proto-Oncogene Proteins c-raf Human genes 0.000 description 1
- 108010029869 Proto-Oncogene Proteins c-raf Proteins 0.000 description 1
- 108700020471 RNA-Binding Proteins Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102000009661 Repressor Proteins Human genes 0.000 description 1
- 108010034634 Repressor Proteins Proteins 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 108010047827 Sialic Acid Binding Immunoglobulin-like Lectins Proteins 0.000 description 1
- 102000007073 Sialic Acid Binding Immunoglobulin-like Lectins Human genes 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 241000186983 Streptomyces avidinii Species 0.000 description 1
- 102000008685 T Cell Transcription Factor 1 Human genes 0.000 description 1
- 108010088184 T Cell Transcription Factor 1 Proteins 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- 102100024219 T-cell surface glycoprotein CD1a Human genes 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- 108010032099 V(D)J recombination activating protein 2 Proteins 0.000 description 1
- 102100029591 V(D)J recombination-activating protein 2 Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 102000013814 Wnt Human genes 0.000 description 1
- 108050003627 Wnt Proteins 0.000 description 1
- 102000007624 ZAP-70 Protein-Tyrosine Kinase Human genes 0.000 description 1
- 108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 150000001615 biotins Chemical class 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000023402 cell communication Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000695 excitation spectrum Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000012757 fluorescence staining Methods 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 210000000285 follicular dendritic cell Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000034435 immune system development Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000013394 immunophenotyping Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000002664 langerhans' cell Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 102000026415 nucleotide binding proteins Human genes 0.000 description 1
- 108091014756 nucleotide binding proteins Proteins 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 210000002306 phycobilisome Anatomy 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- 238000010379 pull-down assay Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000000985 reactive dye Substances 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000008960 regulation of mRNA stability Effects 0.000 description 1
- 230000006803 regulation of nuclear mRNA splicing, via spliceosome Effects 0.000 description 1
- 230000024769 regulation of transport Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002165 resonance energy transfer Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000001086 yeast two-hybrid system Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
- C12Q1/6818—Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y10/00—Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
- G01N33/54333—Modification of conditions of immunological binding reaction, e.g. use of more than one type of particle, use of chemical agents to improve binding, choice of incubation time or application of magnetic field during binding reaction
Definitions
- This invention relates to the field of detecting interacting proteins and other closely associated molecules. More specifically, the invention relates to assessing close interactions between macromolecules at the single cell level.
- the recent abundance of genome sequence data has necessitated systematic proteomics to decipher the encoded protein networks that dictate cellular function. These include cell-cell interaction, cell activation, cell cycle, signalling pathways, cell proliferation, differentiation, apoptosis, development and many other cellular functions.
- Initial steps in elucidating the function of an uncharacterized gene product, i.e. a novel protein often involve studying its interaction with other proteins. Whereas the elucidation of a protein network provides a wealth of information regarding the players, insight into interactions between individual molecules is essential for understanding the contribution of each molecule to a molecular network.
- Co-localization studies are often employed to monitor the proximity of one protein of interest to another protein of interest.
- Co-localization data are also useful as a means of evaluating protein information inferred from genetic data e.g., supporting or refuting putative protein interactions suggested from for example a yeast two-hybrid analysis.
- Co-localization of intracellular proteins can be assessed by use of differentially labelled antibodies specifically reactive with endogenous proteins of interest which can be visually detected by fluorescence microscopy via immunofluorescence.
- fixed cells are treated first with a set primary antibodies specific to proteins of interest, and then with a set of secondary antibodies conjugated with fluorescent dye.
- Antibodies directly conjugated with a fluorescent dye may also be used.
- dyes should differ in excitation and emission wavelength, so that they can be excited independently and observed in separate fluorescent channels.
- genes encoding the proteins of interest may be fused to a reporter gene encoding a reported protein, like green fluorescent protein (GFP), or tagged with an epitope, such as Myc or HA. Reporters and epitope tags are fused routinely to either the N or C termini of target genes.
- Dyes specific to membranes or nucleic acids may additionally be used to reveal the cell organelles, e.g. the nucleus can be visualized by DNA staining with DAPI. Images are generally collected on a confocal microscope which ensures that observed proteins are in the same focal plane, and therefore co-localization, if any, is real. Co-localization is revealed by overlap in colours.
- Co-localization of cell surface molecules can also be determined via so-called 'patching / capping' experiments. Briefly, upon addition of a multivalent ligand for protein A to viable cells, a clump or patch of protein A molecules assembles in the membrane. If the cell is alive and metabolising actively, patches are formed which can further assemble into a cap in a process called "capping", preferably occurring at 37 degrees Celsius. The patches / cap can be stained by indirect fluorescence staining procedures. Subsequently, cells may be counterstained at 4 degrees Celsius (to retain the patches/cap) with a dye-conjugated antibody against protein B to evaluate whether protein B has moved together i.e.
- FRET fluorescence resonance energy transfer
- a dye called a “donor” transfers, after excitation by a light source, its energy to another dye (called “acceptor”).
- acceptor another dye
- the energy transfer occurs when the emission spectrum of the donor dye overlaps significantly with the excitation spectrum of the acceptor.
- Sufficiently close juxtaposition of the two dyes generally closer than 100 ⁇ ngstrom, but preferably closer than 50 ⁇ ngstrom, is essential for energy transfer between the donor/acceptor pair.
- One ⁇ ngstrom a metric unit of length, is equal to 0.1 nanometer or 10 -10 meter.
- FRET is usually based on the interaction between donor and acceptor dyes that are both fluorescent.
- FRET can also be detected by the quenching of donor fluorescence using a nonfluorescent acceptor dye.
- Nonfluorescent acceptor dyes are in general advantageous because they eliminate the background fluorescence that results from direct acceptor excitation.
- use of a nonfluorescent acceptor involves measuring a decrease in donor fluorescence. Generally, detection of a decreased signal is less sensitive compared to detection of an increased signal. Therefore, a method according to the invention is preferably practiced using a fluorescent donor and a fluorescent acceptor dye.
- FRET energy transfer efficiency is inversely proportional to the sixth power of the distance between the donor and the acceptor.
- FRET first described by Förster, has become extremely important for modern cell biology because FRET allows to measure distances between molecules on a scale of a few nanometers. This is far below the resolution limit of modern optical far field microscopy, which currently is at approximately 100 nm.
- FRET technology has been used for detection of various individual (bio)molecules.
- US 6,235,535 discloses a fluorescence-based immunoassay method for the detection of an analyte in a biological sample.
- the method is based on the ability of a multivalent analyte (antigen) to induce aggregation of identical receptor molecules (antibodies) labelled with a fluorophore, which molecules are immobilized onto yet freely mobile on a lipid membrane. Antigen-induced aggregation of the receptors causes FRET to take place. Also in US 2002/0081617 , antibodies directed to the same epitope but labelled with either a donor of acceptor dye are immobilized, in this case onto beads. Upon addition of an analyte (antigen) of interest, the analyte functions as a bridge and brings a pair of antibodies into close proximity of each other which leads to FRET.
- US 6,235,535 and US 2002/0081617 both relate to the detection or measurement of an analyte using immobilized, dye-conjugated probes and FRET-based detection methods. Since the probe sets of US 6,235,535 and US 2002/0081617 are directed to a single molecule or molecular epitope, they are essentially not suitable for detecting distinct interacting molecules.
- FRET Fluorescence Activated FRET
- the extreme sensitivity of the FRET process on the distance between molecules renders it a very useful tool for the resolution of intracellular protein arrangements and protein dynamics.
- the presence of FRET indicates intermolecular interaction since it is observable only for nanometer-scale fluorophore distance. This implies in particular that simple co-localization of two molecules, e.g. proteins, is not sufficient to yield energy transfer.
- FRET is a technique that can give clear, unambiguous answers to questions about protein-protein interactions. FRET measurements can be used to determine protein interactions at the cell surface.
- FRET technology was also used in a highly specific fluorescence lifetime imaging microscopy (FLIM) method for monitoring epidermal growth factor receptor (EGFR) phosphorylation in cells.
- FLIM fluorescence lifetime imaging microscopy
- fluorescently tagged proteins have proven to be very useful, they do have limitations, such as their significant size (>200 amino acids). Also, the overall folding and tertiary structure of a tagged protein may be different from that of the native, non-tagged protein. This may result in different, erroneous interactions with other molecules. Drawing conclusions with respect to the addressed protein-protein interactions on the basis of FRET data between pairs of tagged proteins, as well as performing comparisons with normal cellular functions in living cells, is justified only if the recombinant, tagged proteins behave similar to the corresponding endogenous wild-type proteins.
- the expressed fluorescently-tagged protein should reveal the same intracellular distribution as the wild-type protein; the expression of the tagged protein per se should not induce or inhibit cellular functions and the tagged protein expressed in the cell should not create significant background FRET-signal e.g. due to overexpression, pH shift etc.
- Another major drawback of the use of recombinant, tagged proteins lies in the fact that it requires (co-)transfection of a chimeric construct(s) of interest into a cell and selection of a cell showing adequate expression of a construct to yield a functional protein. Obviously, such a system does not allow detection of an endogenous protein and can therefore not be used to evaluate endogenous interacting molecules.
- a pair of antibody conjugates was used to study cell surface proteins on human lymphocytes: the CD8alpha chain detected by pairs of antibodies against different epitopes; the very late antigen 4 (VLA4), a heterodimeric alpha 4 beta 1 integrin, was detected via FRET between antibody conjugate pairs specific for either integrin beta 1 (CD29) or integrin alpha 4 (CD49d); association of T-cell receptor (TCR) with a soluble antigen ligand was detected by FRET when anti-TCR antibody and MHC class I/peptide complexes were used.
- VLA4 very late antigen 4
- TCR T-cell receptor
- TCR T-cell receptor
- MHC class I/peptide complexes were used.
- antibody mediated FRET technology was used to measure the interaction of c-kit receptor with its ligand SCF (stem cell factor). 7 Thus far, antibody-mediated FRET technology has not been applied to detect intracellular protein-protein interactions.
- FRET technology has also been applied for the detection of a protein-DNA interaction on the basis of a so-called indirect binding principle. For example, it was used to monitor the interaction between the p65 subunit of the transcription factor, NF-kappaB and its DNA binding site.
- NF-kappaB is of great relevance to the pharmaceutical sector due to its ability to regulate a number of genes involved in various immune and inflammatory responses. As such NF-kappaB has been implicated in several disease states including various viral infections (HIV), arthritis and cancer.
- An anti-GST antibody labelled with Cy3 is allowed to interact with an affinity purified GST fusion protein of p65 and GST (p65GST).
- dsDNA doublestranded DNA sequence which contains the NF-kappaB binding site was singly labelled with Cy5 at the 5' end of the coding sequence. This was then incubated with a Cy3 labelled antibody and p65GST. The reaction was done either in the presence or absence of unlabelled non-specific or specific competitor dsDNA. In the absence of either competitor, binding by p65-GST resulted in FRET between the Cy3 donor molecules on anti-GST and Cy5 acceptor molecule on dsDNA.
- the present invention provides the insight that dye-conjugated probes, e.g. antibodies, can be used to detect interacting endogenous molecules when these probes are sufficiently juxtaposed.
- a set of at least a first and a second molecular probe each probe provided with a dye wherein said dyes together allow energy transfer; said probes being provided with a reactive group capable of binding a bridging substance allowing juxtaposing said at least first and second probe wherein said reactive group allows to modulate juxtaposing of said probes such that there is an increased likelihood of energy transfer between them.
- a molecular probe is capable of specifically binding to an interacting molecule of interest via its so-called binding domain.
- a reactive group can be used to modulate juxtapositioning of the probes.
- a reactive group has no or a minimal tendency to compete with the binding domain for binding to an interacting molecule.
- a set of probes of the invention can be distinguished from known sets of antibody probes which are clustered or juxtaposed by the mere binding to one antigenic molecule or complex.
- a reactive group preferably remains available for modulating the spatial organization of juxtaposed probes after the probes are bound.to interacting molecules.
- the invention provides a method for detecting at least two interacting molecules in a cell using a set of at least a first and a second molecular probe, each probe capable of binding to a different molecule, each probe further provided with a dye wherein said dyes together allow energy transfer, said probes being provided with a reactive group allowing to modulate juxtaposing of said at least first and said second probe such that there is an increased likelihood of energy transfer between said dyes, comprising providing a set of probes, providing a sample comprising a cell, contacting said sample with said probes under conditions that allow juxtaposing of said probes on said interacting molecules, removing any unbound and any non-specifically bound probe and detecting juxtaposition of said probes via FRET to determine the interaction between said molecules.
- a suitable probe is a substance capable of specifically binding to a specific molecule.
- a specific molecule may be a protein, nucleic acid, lipid, carbohydrate.
- a nucleic acid may be DNA or RNA.
- a probe can be a conventional (poly- or monoclonal) or a synthetic antibody or a binding fragment functionally equivalent thereto, such as a Fab', Fab or a single chain Fv fragment.
- a probe according to the present invention in fact comprises any type of binding molecule capable of specifically binding to or hybridising with a specific molecule such as a protein, a nucleic acid, a lipid molecule, a carbohydrate moiety or an other class of biomolecules.
- the invention can be practiced with a nucleic acid probe capable of hybridising to a specific nucleic acid sequence.
- Various nucleic acid probes can be used in the invention to identify genetic elements. These include traditional probes such as small strands of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) as well as a peptide nucleic acid (PNA).
- PNA is related to, but distinct from, DNA.
- the chemical structure of PNA differs from DNA in that a peptide-like backbone instead of a phosphate backbone, supports the nucleic acid bases.
- Nucleic acid probes to be used according to the invention can be selected on the basis of sequence analysis of nucleic acid regions to be investigated. The probes can be synthesised and labelled according to methods known in the art. Successful binding of a probe to a nucleic acid region within a sample identifies the gene segment.
- the term dye refers to a substituent which, in concert with another dye, can be used for energy transfer e.g. FRET analysis. It is preferred that at least one of said dyes is a fluorochrome.
- a donor dye molecule must absorb light and transfer it through the resonance of excited electrons to a second dye molecule, the acceptor.
- the fluorescence emission wavelength of the donor must be lower than the excitation wavelength of the acceptor; that is, the process must be energetically "downhill".
- FRET is usually based on the interaction between donor and acceptor dyes that are both fluorescent
- nonfluorescent acceptor dyes may also be used. These can sometimes be advantageous because they eliminate the background fluorescence that results from direct (i.e., nonsensitized) acceptor excitation.
- fluorochromes are fluorescein labels, e.g.
- Other dyes of interest are quantum dot dyes, which come in a nearly unlimited palette of colours.
- Suitable dyes are those suitable for analysis by conventional flow cytometry. FRET pairs which can be used for detection by most conventional flow cytometers are discussed in e.g. Szollosi et al. 8 Preferred combinations of fluorochromes for practicing the present invention comprise those dyes used in the classical tandem conjugates, also referred to as duochromes 9 .
- a sample is contacted with two antibodies, one against protein A and the other against protein B to monitor an interaction between protein A and protein B.
- One antibody is labeled with a FRET donor dye and the other with a FRET acceptor dye. Only when protein A is in close proximity of protein B, e.g. when both are part of a larger protein complex, the two antibodies become sufficiently close together ('juxtaposed') which allows the donor/acceptor pair to induce a detectable FRET fluorescence signal.
- a complete antibody is a large Y-shaped protein molecule, ⁇ 150kDa in size, made up of 2 heavy chains and 2 light chains.
- antibody molecules can bridge a relatively large distance.
- the flexibility of an antibody may decrease the probability of energy transfer between a pair of dyes that are conjugated to juxtaposed antibody probes.
- the size of a probe or a dye might interfere with energy transfer via exerting negative steric effects.
- a dye conjugate like a fluorescent probe, it is in general not possible to control the site of conjugation.
- a dye moiety can become attached to different parts of the antibody molecule.
- the spatial orientation of dyes on probes can be favourable or unfavourable for energy transfer efficiency i.e.
- dyes attached to probes need not necessarily be within energy transfer distance of each other.
- FRET FRET was detected in all cases albeit that the energy transfer efficiency observed was always less than 10%. Possibly, this was due to steric effects associated with the size and structure of PE and APC.
- a close juxtapositioning of FRET probes is a requirement for energy transfer between a donor/acceptor pair, it may not always be sufficient for achieving efficient energy transfer between the dyes attached to said juxtaposed probes e.g. between fluorochrome-conjugated antibodies on interacting molecules or on molecules that are part of a complex.
- the invention now provides a solution for this problem by providing the insight that juxtaposing of probes can be stabilized and / or enhanced by providing the probes with a reactive group.
- a set of at least a first and a second molecular probe is provided, each probe provided with a dye wherein said dyes together allow energy transfer; said probes comprising a reactive group allowing juxtaposing of said at least first and second probe wherein said reactive group allows to modulate juxtaposing said probes such that there is an increased likelihood of energy transfer between them.
- Use of such a probe set yields an improved sensitivity of detecting juxtaposed probes by measuring energy transfer compared to use of probes without a reactive group.
- the term "reactive group” refers to a moiety which allows modulating the spatial organization of FRET dyes on the probes such that there is an increase in the probability of energy transfer to occur and / or an increase in energy transfer efficiency.
- the spatial organization refers to both the distance between the dyes as well as to their relative orientation. Modulating the spatial organization includes adjusting and stabilizing the spatial organization of dyes.
- One of the primary conditions for energy transfer to occur is that donor and acceptor molecules must be in close proximity, typically 2-100 ⁇ .
- a reactive group allows bringing said dyes within a distance of 100 ⁇ of each other, more preferably within 50 ⁇ of each other but most preferably within a distance of 20 ⁇ of each other. It is therefore preferred that a reactive group is small, like smaller than 10 kiloDalton (kD), better smaller than 5 kDa, even better smaller than 2 kDa or best smaller than 1 kDa.
- a reactive group may be capable of modulating juxtaposed probes (probes bound via their binding domains to interacting molecules) such that there is an increased likelihood of energy transfer between dyes by directly interacting with an other probe.
- a reactive group of a first probe binds to a part of a juxtaposed second probe to form a stable complex between said probes in a spatial orientation that is favourable for FRET to occur.
- the site of modification is mainly determined by the presence and accessibility of a certain residue via which a reactive group is conjugated to a probe, e.g. via primary amines or via thiol groups.
- an antibody probe may contain a reactive group at either the constant and /or the variable region of the immunoglobulin. It is conceivable that not every site is equally suitable for interacting with a second probe e.g. due to steric hindrance. Therefore, it is preferred that a probe is provided with a multiplicity of reactive groups to statistically increase its capacity to interact with an other probe.
- a first probe can bind directly to at least a second probe
- a set of probes A and B are used to detect an interaction between molecule A and B in a sample.
- said sample is contacted with probe A comprising a reactive group to allow recognition of and binding to molecule A.
- any unbound and any non-specifically bound probe A is removed by repeated washing steps.
- said sample is contacted with probe B specifically reactive with molecule B under conditions allowing juxtaposing of probe A and B on interacting molecules A and B.
- any unbound and any non-specifically bound probe B may be removed by repeated washing steps.
- a reactive group of probe A may interact with a juxtaposed probe B to modulate the spatial orientation of the dyes present on said probes such that there is an increased likelihood of energy transfer between them.
- this method can be used to detect closely interacting molecules, it shall be clear that such a procedure, involving multiple separate contacting and washing steps, is rather laborious and time-consuming.
- probes are capable of directly interacting with each other, a significant background signal can be expected because, generally speaking, specific probes bind to their target molecules irrespective of whether these molecules interact.
- a probe A bound to molecule A not interacting with molecule B might still recruit probe B and allow energy transfer between dyes conjugated to probes A and B.
- probe A is efficiently removed following contacting the sample with probe A
- an unwanted interaction between probe A and B can occur upon subsequent contacting said sample with probe B. Both events may result in a detectable energy transfer signal despite the fact that probe B is not juxtaposed to probe A on interacting molecules.
- a reactive group of at least a first probe is not directly or immediately reactive with a second probe in order to avoid self association of said probes.
- This is also advantageous for an optimal recognition of interacting molecules by the binding domain of each probe and for juxtaposing said probes on said molecules. Moreover, it avoids untimely energy transfer to occur between directly connected or multimerized probes and decreases an aspecific background signal. This is important to ensure that an energy transfer signal truly reflects juxtaposed probes.
- the invention provides the insight that a probe comprising a reactive group which does not directly interact with an other probe to avoid self association of said probes, is advantageously used in a system comprising a so-called "bridging" substance capable of mediating an interaction between said probes.
- a system comprising a so-called "bridging" substance capable of mediating an interaction between said probes.
- Such a system allows to modulate juxtaposing said probes such that there is an increased likelihood of energy transfer between the dyes on said probes while minimizing the chance of aspecific and / or untimely interactions between probes.
- Use of such a set of probes in combination with a bridging substance has several advantages over use of directly interacting probes. First, an improved specificity and reduced background staining can be achieved.
- probes need to be in a close juxtaposition of each other prior to the addition of said substance i.e. resulting from binding of one probe adjacent to another probe on closely interacting molecules.
- the procedure is faster and easier because no separate contacting steps and washing steps are required for each individual probe. Thus, it permits to contact a sample with a mixture of probes all together in a single action. Likewise, any unbound and any non-specifically bound probes can be removed simultaneously.
- a substance may be any kind of compound capable of binding to or modifying a probe, a reactive group and / or a dye to modulate the spatial organization of dyes on juxtaposed probes such that it is favourable for FRET.
- Said substance allows bringing said dyes within a distance of 2 to 100 ⁇ ngstrom to each other.
- Said substance is preferably added to a sample following binding of dye-conjugated probes to interacting molecules, in an amount effective to modulate the spatial organization of said dyes on juxtaposed probes.
- said substance binds to a reactive group with a high specificity and a high affinity. Also, it is preferred that such a substance is relatively small so that the bridging substance only minimally affects the distance between a pair of dyes and the relative orientation of a pair of dyes.
- each probe provided with a dye wherein said dyes together allow energy transfer; each probe provided with a reactive group.
- a substance is preferably capable of binding, or "bridging", at least two reactive groups.
- each probe within a set of probes is provided with the same reactive group.
- each probe within a set of probes may be provided with a different reactive group but having the same reactivity. This allows the use of one type of bridging substance having at least two identical binding sites for a reactive group.
- a probe is provided with a multiplicity of reactive groups, like two or three or even up to ten reactive groups, enabling said probe to interact with more than one molecule of bridging substance.
- Providing a probe with more than one reactive group will theoretically increase the likelihood of an interaction between said probe and a bridging substance.
- a suitable reactive group or a derivative thereof is commercially available and can be easily and efficiently attached to a probe.
- a particularly interesting reactive group is biotin, with avidin or streptavidin being a particularly suitable bridging substance.
- Avidin is an egg-white derived glycoprotein with a molecular weight of about 68000 daltons and a diameter of 8 to 10 ⁇ ngstrom. It consists of four identical subunit chains.
- One avidin or streptavidin molecule can bind four molecules of biotin.
- Avidin has an extraordinarily high affinity (affinity constant > 10 15 M-1) for biotin. This high affinity assures the user of a rapidly formed and stable complex between avidin and the biotin-labeled probes.
- the protein streptavidin produced by the bacterium Streptomyces avidinii, has a structure very similar to avidin, and also binds biotin tightly. It often exhibits lower non-specific binding, and thus is frequently used in place of avidin. Once a biotin-avidin complex forms, the bond is essentially irreversible.
- the biotin-avidin system is widely used and has proven to be very useful in the detection and localization of antigens, glycoconjugates, and nucleic acids by employing biotinylated antibodies, lectins, or nucleic acid probes. As said, a reactive group with such a small size is advantageous for achieving a close distance between a dye pair.
- Biotin is a vitamin with a molecular weight of only 244 daltons. Furthermore, many biotin molecules can be coupled to a protein, enabling a biotinylated probe to bind more than one molecule of avidin. Avidin, streptavidin and biotin are available from many commercial sources. Various standard procedures for preparing biotin-conjugates are known to those skilled in the art, most of which can be completed within a day. Moreover, commercial biotinylation kits are available which contain all the necessary components for protein biotinylation.
- a suitable substance comprises a molecule capable of binding at least one of each reactive group.
- a binding substance comprises a complex of at least two molecules that can be covalently or non-covalently attached to each other, wherein each molecule is capable of binding to a reactive group.
- a method according to the invention allows detection of at least two interacting molecules in a cell wherein at least one of said molecules is a proteinaceous substance.
- at least one of said molecules is a nucleic acid.
- at least one of said molecules is a lipid or a carbohydrate.
- the invention provides a method to detect the interaction of at least one protein with at least one nucleic acid, such as a DNA-binding protein binding to a specific DNA conformational sequence.
- the family of DNA-binding molecules includes transcriptional activators or repressor proteins as well as other proteins which bind to double- and / or single- stranded DNA. It also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases.
- RNA-binding proteins are required for translation regulation of gene expression. They are involved in multiple post-translational processes such as the regulation of pre-mRNA splicing, mRNA stability and transport of RNAs between nucleus and cytoplasm.
- a probe may be used which binds to an RNA-binding protein, like an antibody against a certain splicing factor, in combination with a second probe which recognizes a specific RNA sequence.
- a FRET signal is produced only when an interaction takes place between the splicing factor and the RNA.
- the method provided permits detection of a protein-nucleic acid interaction at the single cell level. To avoid interference with an interaction between molecules of interest, it is preferred that the binding domains of the probes recognize and bind to a region of the molecules of interest that is distinct from the site of interaction between said molecules.
- probes are provided which can detect the interaction between a protein, such as a carbohydrate binding protein (CBP), and a carbohydrate.
- CBP carbohydrate binding protein
- Protein-carbohydrate interactions are now recognized to be important mediators of cell communication.
- CBPs recognize carbohydrate ligands on glycoproteins and glycolipids. Included are four large families of CBPs, the siglecs, C-type lectins, galectins and the subset of T cell antigen receptors (TCR) that recognize carbohydrate ligands presented by CD1 and MHC antigen presenting molecules.
- TCR T cell antigen receptors
- the present invention concerns a probe set that can be used for the detection of a protein-lipid interaction, at least one probe being reactive with a protein of interest and at least one probe being reactive with a lipid of interest.
- the protein may be an enzyme, such as a lipase, a lipid kinase or a lipid phosphatase, interacting with a lipid substrate.
- the protein probe may comprise an antibody specifically reactive with said protein.
- a lipid probe according to the invention can be a protein moiety with lipid binding properties.
- lipid probes which specifically recognize and bind to a lipid molecule which is involved in signal transduction pathways, like phosphoinositide polyphosphates or lipid second messengers diacylglycerol (DAG) or phosphatidic acid (PA).
- DAG diacylglycerol
- PA phosphatidic acid
- a suitable lipid probe includes a recombinantly produced and purified PH domain.
- PLC protein kinase C
- PA -binding region of Raf-1 kinase A lipid probe comprises an antibody directed against a specific lipid, like a monoclonal antibody specifically reactive with PtdInsP(3). 10 But other lipid probes can be thought of as well.
- a set of dye-conjugated probes according to the invention can be used to detect a wide variety of various signal transduction events, either stable or transient, at the single cell level. These include the interaction of a receptor with one or more other molecules, like receptor-ligand interaction, receptor clustering or multimerization, the interaction of a receptor with an intracellular signalling molecule. Other events to be detected using a method provided herein comprise interaction of various signalling molecules with each other, like the docking of a Src-homology 2 (SH2)-containing protein to a specific phosphotyrosine residue in another protein, or the binding of a Src-homology 3 (SH3 )-containing protein to proline-rich stretch in another protein.
- SH2 Src-homology 2
- SH3 Src-homology 3
- the present method permits to detect interactions between cytoskeletal proteins as well as between nuclear proteins (in the so-called signalosome).
- Activation of a signal transduction pathway often includes protein phosphorylation by tyrosine kinases and/or serine/threonine kinases. Protein phosphorylations can change enzyme activities and protein conformations. The eventual outcome is an alteration in cellular activity and changes in the program of genes expressed within the responding cells.
- a probe comprises a phospho-specific antibody which specifically recognizes a protein in its phosphorylated state.
- a phosphorylated residue may be a tyrosine, serine or threonine residue.
- Phosphospecific antibodies against a wide variety of signalling proteins can be obtained from a number of companies such as Upstate Biotechnology, New England Biolabs, Sigma and many others.
- a Cy3-labeled phosphotyrosine-specific antibody against the Erb receptor tyrosine kinase can be used to specifically detect the activated form of the receptor.
- Suitable probes include a phosphospecific antibody that recognizes only the phosphorylated form of the nuclear transcription factor forkhead in rhabdomyosarcoma (FKHR), protein kinase B (PKB), mitogen-activated protein kinase (MAPK).
- FKHR rhabdomyosarcoma
- PBB protein kinase B
- MAPK mitogen-activated protein kinase
- analogs of nucleotides that serve as substrates or inhibitors of enzymes, and derivatives that selectively bind to regulatory sites of nucleotide-binding proteins have been used as structural and mechanistic probes for isolated proteins. These type of molecules also represent interesting probes for practicing a method according to the invention.
- a method provided herein allows detection of interacting molecules at the single cell level.
- Single cells can be analysed using e.g. flow cytometry or fluorescence microscopy.
- said detection is performed by flow cytometry.
- flow cytometry A major advantage of flow cytometry is that it directly gives quantitative data and that it is very rapid (results can be obtained within a few hours). Detecting energy transfer by flow cytometry allows high throughput analysis of interacting molecules. High throughput flow cytometric detection of molecular interactions at the single cell level allows for time course and dose response studies of one or more of the afore mentioned interactions, such as signal transduction events, transcription factor interactions.
- a method provided allows the detection of molecular interaction at the single cell level in permeabilized and / or fixed cells. Furthermore, because the method provided can detect endogenous molecules, it is especially useful to investigate molecular interactions in primary cells. It can for example be used to discriminate between normal and abnormal cells on the basis of one or more of the above-mentioned interactions.
- the current invention is preferably practiced with a donor / acceptor pair that is suitable for FRET detection by flow cytometry.
- a pair commonly used for FRET includes fluorescein isothiocyanate (FITC) and tetramethylrhodamine isothiocyanate (TRITC).
- FITC fluorescein isothiocyanate
- TRITC tetramethylrhodamine isothiocyanate
- FITC fluorescein isothiocyanate
- TRITC tetramethylrhodamine isothiocyanate
- laser sources for this pair are usually not found on standard flow cytometers.
- R-PE R-phycoerythrin
- API Allophycocyanin
- Phycobiliproteins are produced naturally and are associated with phycobilisomes and are used by different cyanobacteria or algea.
- the PE/APC pair is very promising because 90% of FRET efficiency may be reached in spite of the sizes of PE and APC. Furthermore, this FRET pair can be detected easily on commercially available flow cytometers such as FACSCalibur, LSR, and FACSVantage equipped with two common lasers (or a diode) in a configuration emitting at 488 and 632 nm.
- Detection of energy transfer using flow cytometry or fluorescence activated cell sorting offers the possibility to perform rapid, multiparametric analysis of specific individual cells in a heterogeneous population.
- the detection of multiple fluorescent markers on a cell by flow cytometry provides a powerful tool for single cell analysis and allows subset gating of a target cell population. Selective analysis within a target cell population increases sensitivity of the detection method.
- a method according to the invention can include intracellular staining or staining of a surface marker to define a target cell population in a mixture of cells comprising staining with a fluorescent marker antibody capable of selectively identifying said cellular marker.
- the present method now allows gating of subset of cells that are present in a mixture of cells via immunophenotypic characteristics, i.e. it permits the detection of a interacting molecules in a rare population of cells.
- a method is provided to identify and/ or isolate rare single cells using multiparameter flow cytometry/cell sorting techniques and to characterize molecular interaction at the single-cell level.
- a method provided now allows detection of interacting molecules in a mixture of abnormal cells with normal cells to identify and quantitate abnormal cells based on the basis of an aberrant interaction between molecules. Such a method is particularly suited for application to a number of important problems in immune system development, infectious diseases, cancer and gene therapy.
- cell prior to staining a cell sample with a probe set, cell are labeled with at least one relevant dye-conjugated antibody according to standard procedures in order to define a target cell population in a mixture of cells.
- a mixture of cells comprises living cells.
- a method comprising staining a sample for at least one cellular marker to define a target cell population comprising contacting said sample with a compound capable of selectively binding to a cellular marker.
- a compound capable of selectively binding to a cellular marker.
- such a compound is directly tagged with a fluorescent dye.
- a suitable compound comprises a fluorescently labelled antibody or a binding fragment functionally equivalent thereto.
- a compound capable of selectively binding to a cellular marker can be used which can be detected using a dye-conjugated secondary reagent (e.g. a fluorescently labelled secondary antibody).
- a cellular marker comprises any kind of intracellular or membrane-bound marker which can be used to distinguish a subpopulation of cells in a mixture of cells.
- a cellular marker can be a cluster of differentiation (CD) antigen.
- CD markers are cell surface molecules of among others haemopoietic cells that are distinguishable with monoclonal antibodies.
- Haemopoietic cells comprise thymocytes, dendritic cells, Langerhans' cells, neutrophils, eosinophils, germinal centre B cells, follicular dendritic cells, plasma cells and bone-marrow cells.
- suitable cellular markers comprise CD1, CD3, CD4, CD8, CD10, CD19, CD20, CD33, CD34 and CD117.
- Monoclonal antibodies directed against a large number of human CD markers can be obtained from various suppliers, such as BD Biosciences or Ancell Immunology Research Products, Bayport, USA. Often, antibodies are available that are directly conjugated with a fluorochrome of choice e.g. CD10-PE or CD19-FITC, which is obviously the preferred choice to practice a method according to the invention.
- a FRET probe set according to the invention can be combined with one or more dyes to mediate leukocyte subset gating via immunophenotypic characteristics, e.g. CD10, CD19 and CD20 to accurately define subsets of precursor-B-cells in bone marrow, or CD1, CD4 and CD8 to define subsets of thymocytes, or CD34 and/or CD117 to identify stem/precursor cell populations.
- immunophenotypic characteristics e.g. CD10, CD19 and CD20 to accurately define subsets of precursor-B-cells in bone marrow, or CD1, CD4 and CD8 to define subsets of thymocytes, or CD34 and/or CD117 to identify stem/precursor cell populations.
- the invention provides a method for detecting at least two interacting intracellular molecules using of a set of probes according to the invention, each probe being reactive with a different molecule comprising providing a sample comprising a cell, whereby said sample will be subject to fixation and permeabilization, contacting said preparation with a set of probes each probe capable of binding to a specific molecule under conditions that allow juxtaposing of said probes on said molecules, removing any unbound and any non-specifically bound probe and detecting juxtaposition of said probes via FRET.
- the sample is preferably treated so as to obtain a preservation of the morphology of the material and permeabilization in order to ensure sufficient accessibility of a molecule of interest to a probe.
- fixation may be carried out with a fixative such as formaldehyde.
- the method is practiced to detect intracellular molecules that are positioned within a very short distance of each other, for example within 100 ⁇ ngstrom, preferably within 50 ⁇ ngstrom, more preferably within 20 ⁇ ngstrom.
- a method is provided wherein a sample comprises a primary cell that is obtained from a biological sample.
- a biological sample can be a body fluid sample including blood, bone marrow, urine, cerebrospinal fluid (CSF), saliva. It may also be a tissue sample or a tissue homogenate.
- a sample comprises a cultured cell which may be a cultured primary cell, for example a cultured dermal fibroblast obtained from a skin biopsy.
- a sample may comprise a cultured cell from an established laboratory cell line, like a HeLa, COS, MCF-7 or a Jurkat cell line, which can be obtained from a number of sources such as the American Type Culture Collection (ATCC; see www.atcc.org for an online catalog).
- ATCC American Type Culture Collection
- the invention provides a method to prepare a probe set, comprising contacting each probe with a suitable dye or a derivative thereof to form a conjugate between said probe and said dye and purifying said conjugate from excess dye further comprising contacting at least one probe with a suitable reactive group or a derivative thereof to form a conjugate between said probe and said reactive group and purifying said conjugate from excess reactive group.
- a probe may comprise a conventional (poly- or monoclonal) or a synthetic antibody or other binding molecule, a nucleic acid binding probe, a peptide nucleic acid probe capable of hybridising to a specific nucleic acid sequence, a lipid binding molecule, a carbohydrate binding molecule.
- the present invention is advantageously carried out using probes with minimal negative steric effects on energy transfer efficiency between dyes attached to the probes.
- an antibody probe smaller than a complete IgG such as a Fab', Fab, a single chain Fv fragment or a diabody (scFv dimer) may advantageously be used.
- a low molecular weight fluorescent FRET pair can be used.
- the most convenient and widely used functional group for the labelling of biological molecules is a primary amino group. This can be provided by the epsilon-amino group of a lysine residue, or the free N-terminus of a peptide / protein.
- oligonucleotides it is possible to introduce primary amine containing modifier groups during automated synthesis of, for example, oligonucleotides.
- Stable active esters of fluor labelling species that may be stored as solid materials, in particular N-hydroxysuccinimide (NHS) esters have been extensively used over many years for the acylation of such amino groups.
- N-hydroxysuccinimide (NHS) esters have been extensively used over many years for the acylation of such amino groups.
- thiol containing groups such as those contained in cysteine residues or, as with primary amino groups, those introduced as modifiers during automated synthesis (of for example oligonucleotides) can be specifically targeted by maleimide labelling reagents (for example of Cy3 and Cy5). It is not always feasible to consider the use of either primary amino or thiol labelling on all biological molecules.
- a further common route for labelling of, for example, carbohydrate species is via an aldehyde group targeted by hydr
- a commercial kit may suitably be used for obtaining a probe set comprising at least two probes, each probe provided with a dye and additionally provided with a reactive group.
- labelling and purifying probe conjugates with such labelling kits can be readily accomplished in under three hours, with very little hands-on time.
- a kit available for labelling a proteinaceous probe e.g. an antibody or a peptide, with a fluorescent dye (www.probes.com/handbook/tables/1570.html ).
- the amount of dye necessary for the desired proteinaceous sample is calculated using the guidelines outlined in the kit's protocol.
- a reactive dye has a succinimidyl ester moiety that reacts efficiently with primary amines of a proteinaceous substance to form a stable dye-conjugate.
- Purification of a conjugate can be easily accomplished using a spin column or a size-exclusion spin column.
- the final coupling ratio can be determined according to standard procedures known to those skilled in the art.
- a dye to protein ration of approximately 2.5 to 1 often results in the retention of the ability of the probe to specifically recognize a molecule and in sufficient fluorescence for use of the FRET technique.
- various commercial kits are available which can be used for labelling a probe with a reactive group, such as biotin.
- the biotin-XX sulfosuccinimidyl ester (SSE) is water soluble and reacts with a primary amine to form a stable biotin conjugate.
- the biotin-XX SSE has a 14-atom spacer that enhances the binding of biotin derivatives to avidin's relatively deep binding sites.
- a labelling kit typically contains a ready-to-use spin column for purification of a biotinylated probe from excess reagents.
- the invention also provides a diagnostic test kit for the determination of interacting molecules in a biological sample comprising a set of probes according to the invention.
- the test kit provided comprising a probe set for FRET-mediated detection of interacting molecules is combined with one or more dye-conjugated antibodies that can be used for defining a target cell population within a mixture of cells.
- the sample comprises a biological sample.
- it permits identification and quantification of abnormal cells in a mixture of abnormal cells with normal cells, e.g. on the basis of defined abnormal signalling complexes.
- Many different types of abnormal signaling complexes can be detected in diagnostic applications using a method according to the invention. For example, the interaction of the RAG1 and RAG2 proteins in lymphoid leukemias that have ongoing rearrangements can be evaluated.
- a method as provided herein provides means for monitoring, optionally at the single cell level, normal and pathological Wnt signaling, e.g. in colon carcinomas, melanomas, prostate cancer, breast cancer etc.
- a method or a probe set of the invention is advantageously used in the area of drug discovery, e.g. to select a (candidate) drug compound from among a library of compounds.
- biopharmaceutical companies need a rapid system for screening the target against libraries of compounds to identify those compounds that will have an effect on the target and that demonstrate the potential to become effective drugs.
- a FRET based method of the invention is used to screen for compounds which affect the interaction between two or more molecules in a cell, e.g. compounds that can stimulate or inhibit the formation of signaling complexes such as the signalosome.
- a probe set comprising a first probe that is reactive with a first protein of the signaling complex and a second probe that is reactive with a second protein protein of the complex.
- the first and second protein interact such that the dye-conjugated probes are juxtaposed and a FRET signal can be detected.
- a compound e.g. a drug candidate molecule
- the interaction between proteins within the complex is disrupted.
- the protein-bound probes are no longer juxtaposed and FRET no longer occurs.
- a similar approach can be undertaken to screen for compounds which stimulate or enhance an interaction between molecules.
- a method as provided herein is used to detect the interaction between a compound (drug) and its target, i.e. the interacting molecules are the compound and the target.
- the interacting molecules are the compound and the target.
- This requires a set of probes wherein one probe is reactive with the compound and another probe that is reactive with the target (protein), for instance a compound-specific antibody probe and a target-specific antibody probe may be used.
- a compound-specific antibody probe and a target-specific antibody probe may be used. It can be imagined that the development of specific antibodies for hundreds of different compounds to be screened is not very attractive in e.g. a high throughput screening setting.
- one may provide different compounds with an identical (epitope) tag such that only one (antibody) probe directed against the tag can be used together with a target-specific probe for detecting the interaction between the compound and its target.
- the invention provides a method for the detection of interacting proteins and other molecules using a set of at least a first and a second probe each probe provided with a dye wherein said dyes together allow energy transfer; at least said probes being provided with a reactive group wherein said reactive group allows to modulate juxtaposing of said probes such that there is an increased likelihood of energy transfer between them.
- a probe set according to the invention comprises a set of two dye-conjugated antibodies, each antibody additionally provided with a reactive group. To exemplify the invention, we will describe the preparation of such a set of probes.
- an antibody is known to those skilled in the art, e.g. using hybridoma technology or phage display.
- an immunogen such as a recombinant protein or a synthetic peptide.
- the animal's immune response is monitored by taking test bleeds and determining the titer of the reactivity.
- blood is collected from the animal and antisera are prepared. Further fractionation of the antisera to enrich for antibodies reactive to the protein can be done if desired. See e.g. Harlow et al. Antibodies. A Laboratory Manual, Cold Spring Harbor Publications, New York (1988 ).
- Monoclonal antibodies can be obtained by various techniques familiar to those skilled in the art. Antibodies obtained can be characterised conventional immunodiagnostic techniques e.g. by Western blotting using lysates of cells expressing a recombinant fusion protein or by ELISA.
- Biotin is typically conjugated to proteins via primary amines (i.e., lysines). Usually, between 3 and 6 biotin molecules are conjugated to each antibody. Dialyze or exchange over a column the antibody in 100 mM carbonate, pH 8.4. Measure the antibody concentration after buffer equilibration. (For IgG, 1 mg/ml has an A(280) of 1.4). If the antibody concentration is less than 1 mg/ml, the conjugation will probably be sub-optimal. If necessary, dilute the antibody to a concentration of 4 mg/ml.
- primary amines i.e., lysines
- Cy5 conjugation of an antibody probe is given but of course many other fluorochromes can chosen.
- the entire conjugation can typically be performed in about a half-day.
- the reactive Cy5 molecule is unstable. Open a vial, and weigh out the amount you need (typically, 1 or 2 mg is more than enough). Reseal the vial and store under desiccant at 4 degrees Celsius. Immediately dissolve the Cy5 in DMSO at a concentration of 10 mg/ml.
- Cy5 is covalently coupled to primary amines (lysines) of the immunoglobulin. Dissolve the Cy5 (Cy5-bis-OSU, N,N'-biscarboxypentyl-5,5'-disulfonato-indodicarbocyanine, Amersham Life Science) in anhydrous DMSO (dimethyl sulfoxide, Aldrich) immediately before use, at a concentration of 10 mg/ml. Do not delay between weighing out the Cy5 and dissolving it in DMSO; likewise, do not delay the addition of the solubilized material to the antibody. For the optimal ratio of 5:1, add 40 ⁇ g Cy5 per mg of antibody; mix immediately.
- DMSO dimethyl sulfoxide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Nanotechnology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Mathematical Physics (AREA)
- Theoretical Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medical Informatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Abstract
Description
- This invention relates to the field of detecting interacting proteins and other closely associated molecules. More specifically, the invention relates to assessing close interactions between macromolecules at the single cell level. The recent abundance of genome sequence data has necessitated systematic proteomics to decipher the encoded protein networks that dictate cellular function. These include cell-cell interaction, cell activation, cell cycle, signalling pathways, cell proliferation, differentiation, apoptosis, development and many other cellular functions. Initial steps in elucidating the function of an uncharacterized gene product, i.e. a novel protein, often involve studying its interaction with other proteins. Whereas the elucidation of a protein network provides a wealth of information regarding the players, insight into interactions between individual molecules is essential for understanding the contribution of each molecule to a molecular network.
- Co-localization studies are often employed to monitor the proximity of one protein of interest to another protein of interest. Co-localization data are also useful as a means of evaluating protein information inferred from genetic data e.g., supporting or refuting putative protein interactions suggested from for example a yeast two-hybrid analysis. Co-localization of intracellular proteins can be assessed by use of differentially labelled antibodies specifically reactive with endogenous proteins of interest which can be visually detected by fluorescence microscopy via immunofluorescence. Hereto, fixed cells are treated first with a set primary antibodies specific to proteins of interest, and then with a set of secondary antibodies conjugated with fluorescent dye. Antibodies directly conjugated with a fluorescent dye may also be used. Those dyes should differ in excitation and emission wavelength, so that they can be excited independently and observed in separate fluorescent channels. Alternatively, genes encoding the proteins of interest may be fused to a reporter gene encoding a reported protein, like green fluorescent protein (GFP), or tagged with an epitope, such as Myc or HA. Reporters and epitope tags are fused routinely to either the N or C termini of target genes. Dyes specific to membranes or nucleic acids may additionally be used to reveal the cell organelles, e.g. the nucleus can be visualized by DNA staining with DAPI. Images are generally collected on a confocal microscope which ensures that observed proteins are in the same focal plane, and therefore co-localization, if any, is real. Co-localization is revealed by overlap in colours.
- However, it should be emphasized that the resolution of confocal microscopy only allows to detect a global co-localization of proteins and does not necessarily prove close interaction. Overlapping colours do not necessarily imply interacting proteins, i.e. positioning of the proteins within a very short distance, for instance in the range of 3 to 100 Ångstrom. Therefore, co-localization studies routinely require supplementary analysis to investigate whether co-localized molecules represent truly interacting partners. Typical standard biochemical techniques to evaluate putative interacting molecules include co-immunoprecipitation experiments, affinity pull down assays and affinity chromatography.
- Co-localization of cell surface molecules, e.g. proteins A and B, can also be determined via so-called 'patching / capping' experiments. Briefly, upon addition of a multivalent ligand for protein A to viable cells, a clump or patch of protein A molecules assembles in the membrane. If the cell is alive and metabolising actively, patches are formed which can further assemble into a cap in a process called "capping", preferably occurring at 37 degrees Celsius. The patches / cap can be stained by indirect fluorescence staining procedures. Subsequently, cells may be counterstained at 4 degrees Celsius (to retain the patches/cap) with a dye-conjugated antibody against protein B to evaluate whether protein B has moved together i.e. is colocalized with the 'patched/capped' protein A or whether protein B is still diffusely distributed on the cell surface.1 Although this method works in practice for assessing co-localization of surface membrane proteins, it is time consuming, needs experience and can only be evaluated by dye microscopy, not by flow cytometry. Furthermore, microscopic procedures are not suitable as a high throughput method for the evaluation of interacting molecules.
- A particularly elegant method to detect closely interacting molecules involves fluorescence resonance energy transfer (FRET). In FRET, a dye (called a "donor") transfers, after excitation by a light source, its energy to another dye (called "acceptor"). The energy transfer occurs when the emission spectrum of the donor dye overlaps significantly with the excitation spectrum of the acceptor. Sufficiently close juxtaposition of the two dyes, generally closer than 100 Ångstrom, but preferably closer than 50 Ångstrom, is essential for energy transfer between the donor/acceptor pair. One Ångstrom, a metric unit of length, is equal to 0.1 nanometer or 10-10 meter. FRET is usually based on the interaction between donor and acceptor dyes that are both fluorescent. However, FRET can also be detected by the quenching of donor fluorescence using a nonfluorescent acceptor dye. Nonfluorescent acceptor dyes are in general advantageous because they eliminate the background fluorescence that results from direct acceptor excitation. In the present invention, it is possible to monitor juxtaposed probes on interacting molecules using a fluorescent donor dye and a nonfluorescent acceptor dye. Specific binding of a set of probes to non-interacting molecules will give a basal fluorescence signal. Upon close interaction of the molecules, FRET between the probes will quench the donor fluorescence. Rather than measuring an increase in acceptor fluorescence, use of a nonfluorescent acceptor involves measuring a decrease in donor fluorescence. Generally, detection of a decreased signal is less sensitive compared to detection of an increased signal. Therefore, a method according to the invention is preferably practiced using a fluorescent donor and a fluorescent acceptor dye.
- FRET energy transfer efficiency is inversely proportional to the sixth power of the distance between the donor and the acceptor. FRET, first described by Förster, has become extremely important for modern cell biology because FRET allows to measure distances between molecules on a scale of a few nanometers. This is far below the resolution limit of modern optical far field microscopy, which currently is at approximately 100 nm. FRET technology has been used for detection of various individual (bio)molecules. For example,
US 6,235,535 discloses a fluorescence-based immunoassay method for the detection of an analyte in a biological sample. The method is based on the ability of a multivalent analyte (antigen) to induce aggregation of identical receptor molecules (antibodies) labelled with a fluorophore, which molecules are immobilized onto yet freely mobile on a lipid membrane. Antigen-induced aggregation of the receptors causes FRET to take place. Also inUS 2002/0081617 , antibodies directed to the same epitope but labelled with either a donor of acceptor dye are immobilized, in this case onto beads. Upon addition of an analyte (antigen) of interest, the analyte functions as a bridge and brings a pair of antibodies into close proximity of each other which leads to FRET. Thus,US 6,235,535 andUS 2002/0081617 both relate to the detection or measurement of an analyte using immobilized, dye-conjugated probes and FRET-based detection methods. Since the probe sets ofUS 6,235,535 andUS 2002/0081617 are directed to a single molecule or molecular epitope, they are essentially not suitable for detecting distinct interacting molecules. - The extreme sensitivity of the FRET process on the distance between molecules renders it a very useful tool for the resolution of intracellular protein arrangements and protein dynamics. The presence of FRET indicates intermolecular interaction since it is observable only for nanometer-scale fluorophore distance. This implies in particular that simple co-localization of two molecules, e.g. proteins, is not sufficient to yield energy transfer. FRET is a technique that can give clear, unambiguous answers to questions about protein-protein interactions. FRET measurements can be used to determine protein interactions at the cell surface.2 The 'green revolution' initiated by the introduction of the green fluorescent protein (GFP) from Aequorea victoria and the later developments of GFP-mutants possessing different spectral properties offered the possibility of simultaneous expression of different proteins, artificially tagged with fluorescent donor and acceptor domains in the same cell.3,4 This allowed measurement of their interactions by FRET. The combination of Cyano Fluorescent Protein (CFP) (donor) and Yellow Fluorescent Protein (YFP) (acceptor)- tagged proteins is often used. This FRET pair can be used to monitor the proximity of the two attached fluorescent tags in 3-6 nm. Co-expression of CFP- and YFP-tagged proteins has been successfully used to analyse short time changes in protein-protein interactions, e.g. oligomerization, colocalization, complex formation, activation of kinases and mapping of enzyme activities in living cells. FRET technology was also used in a highly specific fluorescence lifetime imaging microscopy (FLIM) method for monitoring epidermal growth factor receptor (EGFR) phosphorylation in cells. EGFR phosphorylation was monitored using a GFP-tagged EGFR and Cy3-conjugated anti-phosphotyrosine antibodies.5
- Although fluorescently tagged proteins have proven to be very useful, they do have limitations, such as their significant size (>200 amino acids). Also, the overall folding and tertiary structure of a tagged protein may be different from that of the native, non-tagged protein. This may result in different, erroneous interactions with other molecules. Drawing conclusions with respect to the addressed protein-protein interactions on the basis of FRET data between pairs of tagged proteins, as well as performing comparisons with normal cellular functions in living cells, is justified only if the recombinant, tagged proteins behave similar to the corresponding endogenous wild-type proteins. For instance, the expressed fluorescently-tagged protein should reveal the same intracellular distribution as the wild-type protein; the expression of the tagged protein per se should not induce or inhibit cellular functions and the tagged protein expressed in the cell should not create significant background FRET-signal e.g. due to overexpression, pH shift etc. Another major drawback of the use of recombinant, tagged proteins lies in the fact that it requires (co-)transfection of a chimeric construct(s) of interest into a cell and selection of a cell showing adequate expression of a construct to yield a functional protein. Obviously, such a system does not allow detection of an endogenous protein and can therefore not be used to evaluate endogenous interacting molecules. One report describes the use of FRET technology to monitor ligand-induced dimerization of an endogenous cell surface receptor by means of a receptor-specific antibody that was directly conjugated to either the donor dye FITC or the acceptor dye Cy3. 6The ability of a ligand to induce receptor dimerization was assessed by flow cytometric analysis of FRET between FITC and Cy3. A pair of antibody conjugates was used to study cell surface proteins on human lymphocytes: the CD8alpha chain detected by pairs of antibodies against different epitopes; the very late antigen 4 (VLA4), a heterodimeric alpha4beta1 integrin, was detected via FRET between antibody conjugate pairs specific for either integrin beta1 (CD29) or integrin alpha4 (CD49d); association of T-cell receptor (TCR) with a soluble antigen ligand was detected by FRET when anti-TCR antibody and MHC class I/peptide complexes were used. In yet another report, antibody mediated FRET technology was used to measure the interaction of c-kit receptor with its ligand SCF (stem cell factor).7 Thus far, antibody-mediated FRET technology has not been applied to detect intracellular protein-protein interactions.
- FRET technology has also been applied for the detection of a protein-DNA interaction on the basis of a so-called indirect binding principle. For example, it was used to monitor the interaction between the p65 subunit of the transcription factor, NF-kappaB and its DNA binding site. NF-kappaB is of great relevance to the pharmaceutical sector due to its ability to regulate a number of genes involved in various immune and inflammatory responses. As such NF-kappaB has been implicated in several disease states including various viral infections (HIV), arthritis and cancer. An anti-GST antibody labelled with Cy3 (approx. 7-12 dyes per molecule) is allowed to interact with an affinity purified GST fusion protein of p65 and GST (p65GST). A doublestranded DNA (dsDNA) sequence which contains the NF-kappaB binding site was singly labelled with Cy5 at the 5' end of the coding sequence. This was then incubated with a Cy3 labelled antibody and p65GST. The reaction was done either in the presence or absence of unlabelled non-specific or specific competitor dsDNA. In the absence of either competitor, binding by p65-GST resulted in FRET between the Cy3 donor molecules on anti-GST and Cy5 acceptor molecule on dsDNA.
- Thus, it would be advantageous to possess a method that allows the detection of interactions between endogenous intracellular proteins and/or other molecules such as nucleic acids, lipids and/or carbohydrate moieties. Particularly challenging is the detection of intermolecular interactions at the single cell level.
- The present invention provides the insight that dye-conjugated probes, e.g. antibodies, can be used to detect interacting endogenous molecules when these probes are sufficiently juxtaposed. Provided is a set of at least a first and a second molecular probe, each probe provided with a dye wherein said dyes together allow energy transfer; said probes being provided with a reactive group capable of binding a bridging substance allowing juxtaposing said at least first and second probe wherein said reactive group allows to modulate juxtaposing of said probes such that there is an increased likelihood of energy transfer between them.
According to the invention, a molecular probe is capable of specifically binding to an interacting molecule of interest via its so-called binding domain. Following binding of a at least a first and a second probe to a molecule via the binding domain, a reactive group can be used to modulate juxtapositioning of the probes. A reactive group has no or a minimal tendency to compete with the binding domain for binding to an interacting molecule. Herewith, a set of probes of the invention can be distinguished from known sets of antibody probes which are clustered or juxtaposed by the mere binding to one antigenic molecule or complex. A reactive group preferably remains available for modulating the spatial organization of juxtaposed probes after the probes are bound.to interacting molecules. - Further, the invention provides a method for detecting at least two interacting molecules in a cell using a set of at least a first and a second molecular probe, each probe capable of binding to a different molecule, each probe further provided with a dye wherein said dyes together allow energy transfer, said probes being provided with a reactive group allowing to modulate juxtaposing of said at least first and said second probe such that there is an increased likelihood of energy transfer between said dyes, comprising providing a set of probes, providing a sample comprising a cell, contacting said sample with said probes under conditions that allow juxtaposing of said probes on said interacting molecules, removing any unbound and any non-specifically bound probe and detecting juxtaposition of said probes via FRET to determine the interaction between said molecules.
- The method provided is especially suited to assess close interaction between intracellular proteins. However, the method described can also be applied to detect an interaction between other kinds of molecules, like a protein-nucleic acid interaction, provided that a suitable probe is used. A suitable probe is a substance capable of specifically binding to a specific molecule. A specific molecule may be a protein, nucleic acid, lipid, carbohydrate. A nucleic acid may be DNA or RNA. A probe can be a conventional (poly- or monoclonal) or a synthetic antibody or a binding fragment functionally equivalent thereto, such as a Fab', Fab or a single chain Fv fragment. A probe according to the present invention in fact comprises any type of binding molecule capable of specifically binding to or hybridising with a specific molecule such as a protein, a nucleic acid, a lipid molecule, a carbohydrate moiety or an other class of biomolecules.
- For example, the invention can be practiced with a nucleic acid probe capable of hybridising to a specific nucleic acid sequence. Various nucleic acid probes can be used in the invention to identify genetic elements. These include traditional probes such as small strands of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) as well as a peptide nucleic acid (PNA). PNA is related to, but distinct from, DNA. The chemical structure of PNA differs from DNA in that a peptide-like backbone instead of a phosphate backbone, supports the nucleic acid bases. Nucleic acid probes to be used according to the invention can be selected on the basis of sequence analysis of nucleic acid regions to be investigated. The probes can be synthesised and labelled according to methods known in the art. Successful binding of a probe to a nucleic acid region within a sample identifies the gene segment.
- Provided in the invention is a set of at least a first and a second probe each probe provided with a dye allowing energy transfer each probe additionally provided with a reactive group allowing juxtaposing of said first and second probe. In the present context, the term dye refers to a substituent which, in concert with another dye, can be used for energy transfer e.g. FRET analysis. It is preferred that at least one of said dyes is a fluorochrome. To achieve resonance energy transfer, a donor dye molecule must absorb light and transfer it through the resonance of excited electrons to a second dye molecule, the acceptor. For energy transfer to take place, the fluorescence emission wavelength of the donor must be lower than the excitation wavelength of the acceptor; that is, the process must be energetically "downhill". Whereas FRET is usually based on the interaction between donor and acceptor dyes that are both fluorescent, nonfluorescent acceptor dyes may also be used. These can sometimes be advantageous because they eliminate the background fluorescence that results from direct (i.e., nonsensitized) acceptor excitation. Examples of suitable fluorochromes are fluorescein labels, e.g. 5-(and 6)-carboxyfluorescein, 5- or 6- carboxyfluorescein, 6-(fluorescein)-5-(and 6)-carboxamide hexanoic acid and fluorescein isothiocyanate, Alexa Fluor dyes, cyanine dyes such as Cy2, Cy3, Cy5, Cy7, optionally substituted coumarin, R-phycoerythrin, allophycoerythrin, Texas Red and Princeston Red as well as conjugates of R-phycoerythrin and, e.g. Cy5 or Texas Red. See also www.probes.com/handbook/tables/1570.html. Other dyes of interest are quantum dot dyes, which come in a nearly unlimited palette of colours.
- Examples of suitable dyes are those suitable for analysis by conventional flow cytometry. FRET pairs which can be used for detection by most conventional flow cytometers are discussed in e.g. Szollosi et al. 8 Preferred combinations of fluorochromes for practicing the present invention comprise those dyes used in the classical tandem conjugates, also referred to as duochromes 9.
- In a preferred embodiment of the invention, a sample is contacted with two antibodies, one against protein A and the other against protein B to monitor an interaction between protein A and protein B. One antibody is labeled with a FRET donor dye and the other with a FRET acceptor dye. Only when protein A is in close proximity of protein B, e.g. when both are part of a larger protein complex, the two antibodies become sufficiently close together ('juxtaposed') which allows the donor/acceptor pair to induce a detectable FRET fluorescence signal. However, a complete antibody is a large Y-shaped protein molecule, ~150kDa in size, made up of 2 heavy chains and 2 light chains. Owing to the length of an antibody molecule (300 to 400 Ångstrom) and the flexibility of the hinge region, antibody molecules can bridge a relatively large distance. The flexibility of an antibody may decrease the probability of energy transfer between a pair of dyes that are conjugated to juxtaposed antibody probes. Also, the size of a probe or a dye might interfere with energy transfer via exerting negative steric effects. Furthermore, when preparing a dye conjugate, like a fluorescent probe, it is in general not possible to control the site of conjugation. In case of antibody conjugation, a dye moiety can become attached to different parts of the antibody molecule. Depending on the site of dye-conjugation, the spatial orientation of dyes on probes can be favourable or unfavourable for energy transfer efficiency i.e. dyes attached to probes need not necessarily be within energy transfer distance of each other. When the PE/APC FRET pair was evaluated for use in antibody-mediated FRET by analysis of interacting cell surface proteins, FRET was detected in all cases albeit that the energy transfer efficiency observed was always less than 10%. Possibly, this was due to steric effects associated with the size and structure of PE and APC. Thus, whereas a close juxtapositioning of FRET probes is a requirement for energy transfer between a donor/acceptor pair, it may not always be sufficient for achieving efficient energy transfer between the dyes attached to said juxtaposed probes e.g. between fluorochrome-conjugated antibodies on interacting molecules or on molecules that are part of a complex.
- The invention now provides a solution for this problem by providing the insight that juxtaposing of probes can be stabilized and / or enhanced by providing the probes with a reactive group. A set of at least a first and a second molecular probe is provided, each probe provided with a dye wherein said dyes together allow energy transfer; said probes comprising a reactive group allowing juxtaposing of said at least first and second probe wherein said reactive group allows to modulate juxtaposing said probes such that there is an increased likelihood of energy transfer between them. Use of such a probe set yields an improved sensitivity of detecting juxtaposed probes by measuring energy transfer compared to use of probes without a reactive group. In the present context, the term "reactive group" refers to a moiety which allows modulating the spatial organization of FRET dyes on the probes such that there is an increase in the probability of energy transfer to occur and / or an increase in energy transfer efficiency. The spatial organization refers to both the distance between the dyes as well as to their relative orientation. Modulating the spatial organization includes adjusting and stabilizing the spatial organization of dyes. One of the primary conditions for energy transfer to occur is that donor and acceptor molecules must be in close proximity, typically 2-100 Å. In a preferred embodiment, a reactive group allows bringing said dyes within a distance of 100 Å of each other, more preferably within 50 Å of each other but most preferably within a distance of 20 Å of each other. It is therefore preferred that a reactive group is small, like smaller than 10 kiloDalton (kD), better smaller than 5 kDa, even better smaller than 2 kDa or best smaller than 1 kDa.
- A reactive group may be capable of modulating juxtaposed probes (probes bound via their binding domains to interacting molecules) such that there is an increased likelihood of energy transfer between dyes by directly interacting with an other probe. For example, a reactive group of a first probe binds to a part of a juxtaposed second probe to form a stable complex between said probes in a spatial orientation that is favourable for FRET to occur. As mentioned above with respect to the site of dye conjugation, it is often not possible to selectively modify a probe with a reactive group at a defined site. The site of modification is mainly determined by the presence and accessibility of a certain residue via which a reactive group is conjugated to a probe, e.g. via primary amines or via thiol groups. Thus, an antibody probe may contain a reactive group at either the constant and /or the variable region of the immunoglobulin. It is conceivable that not every site is equally suitable for interacting with a second probe e.g. due to steric hindrance. Therefore, it is preferred that a probe is provided with a multiplicity of reactive groups to statistically increase its capacity to interact with an other probe.
- Provided herein is a method for detecting at least two interacting molecules in a cell using a set of at least a first and a second molecular probe, each probe capable of binding to a different molecule, each probe further provided with a dye wherein said dyes together allow energy transfer, said probes provided with a reactive group allowing to modulate juxtaposing said at least first and said second probe such that there is an increased likelihood of energy transfer between said dyes, comprising: providing a set of probes, providing a sample comprising a cell, contacting said sample with said probes under conditions that allow juxtaposing of said probes on said interacting molecules, removing any unbound and any non-specifically bound probe and detecting juxtaposition of said probes via FRET to determine the interaction between said molecules.
- In case a first probe can bind directly to at least a second probe, it is preferred to contact said sample with each probe in consecutive steps with extensive intermittent washing procedures to avoid self association between probes. For example, a set of probes A and B are used to detect an interaction between molecule A and B in a sample. Hereto, said sample is contacted with probe A comprising a reactive group to allow recognition of and binding to molecule A. Next, any unbound and any non-specifically bound probe A is removed by repeated washing steps. Subsequently, said sample is contacted with probe B specifically reactive with molecule B under conditions allowing juxtaposing of probe A and B on interacting molecules A and B. Also here, any unbound and any non-specifically bound probe B may be removed by repeated washing steps. A reactive group of probe A may interact with a juxtaposed probe B to modulate the spatial orientation of the dyes present on said probes such that there is an increased likelihood of energy transfer between them. Although this method can be used to detect closely interacting molecules, it shall be clear that such a procedure, involving multiple separate contacting and washing steps, is rather laborious and time-consuming. Moreover, if probes are capable of directly interacting with each other, a significant background signal can be expected because, generally speaking, specific probes bind to their target molecules irrespective of whether these molecules interact. In the example above, a probe A bound to molecule A not interacting with molecule B might still recruit probe B and allow energy transfer between dyes conjugated to probes A and B. Also, if not all unbound probe A is efficiently removed following contacting the sample with probe A, an unwanted interaction between probe A and B can occur upon subsequent contacting said sample with probe B. Both events may result in a detectable energy transfer signal despite the fact that probe B is not juxtaposed to probe A on interacting molecules.
- Therefore, in a preferred embodiment of the invention, a reactive group of at least a first probe is not directly or immediately reactive with a second probe in order to avoid self association of said probes. This is also advantageous for an optimal recognition of interacting molecules by the binding domain of each probe and for juxtaposing said probes on said molecules. Moreover, it avoids untimely energy transfer to occur between directly connected or multimerized probes and decreases an aspecific background signal. This is important to ensure that an energy transfer signal truly reflects juxtaposed probes.
- The invention provides the insight that a probe comprising a reactive group which does not directly interact with an other probe to avoid self association of said probes, is advantageously used in a system comprising a so-called "bridging" substance capable of mediating an interaction between said probes. Such a system allows to modulate juxtaposing said probes such that there is an increased likelihood of energy transfer between the dyes on said probes while minimizing the chance of aspecific and / or untimely interactions between probes. Use of such a set of probes in combination with a bridging substance has several advantages over use of directly interacting probes. First, an improved specificity and reduced background staining can be achieved. After all, for a reactive group to exert its effect via a bridging substance, probes need to be in a close juxtaposition of each other prior to the addition of said substance i.e. resulting from binding of one probe adjacent to another probe on closely interacting molecules. Second, the procedure is faster and easier because no separate contacting steps and washing steps are required for each individual probe. Thus, it permits to contact a sample with a mixture of probes all together in a single action. Likewise, any unbound and any non-specifically bound probes can be removed simultaneously.
- A substance may be any kind of compound capable of binding to or modifying a probe, a reactive group and / or a dye to modulate the spatial organization of dyes on juxtaposed probes such that it is favourable for FRET. Said substance allows bringing said dyes within a distance of 2 to 100 Ångstrom to each other. Said substance is preferably added to a sample following binding of dye-conjugated probes to interacting molecules, in an amount effective to modulate the spatial organization of said dyes on juxtaposed probes. Advantageously, said substance binds to a reactive group with a high specificity and a high affinity. Also, it is preferred that such a substance is relatively small so that the bridging substance only minimally affects the distance between a pair of dyes and the relative orientation of a pair of dyes.
- Most preferred, as exemplified herein in the detailed description, is a set of at least a first and a second molecular probe, each probe provided with a dye wherein said dyes together allow energy transfer; each probe provided with a reactive group. A substance is preferably capable of binding, or "bridging", at least two reactive groups. In a preferred embodiment, each probe within a set of probes is provided with the same reactive group. Also, each probe within a set of probes may be provided with a different reactive group but having the same reactivity. This allows the use of one type of bridging substance having at least two identical binding sites for a reactive group.
In one embodiment of the invention, a probe is provided with a multiplicity of reactive groups, like two or three or even up to ten reactive groups, enabling said probe to interact with more than one molecule of bridging substance. Providing a probe with more than one reactive group will theoretically increase the likelihood of an interaction between said probe and a bridging substance. Furthermore, for the ease of practicing the present invention, a suitable reactive group or a derivative thereof is commercially available and can be easily and efficiently attached to a probe. - In accordance with the present invention, a particularly interesting reactive group is biotin, with avidin or streptavidin being a particularly suitable bridging substance. Avidin is an egg-white derived glycoprotein with a molecular weight of about 68000 daltons and a diameter of 8 to 10 Ångstrom. It consists of four identical subunit chains. One avidin or streptavidin molecule can bind four molecules of biotin. Avidin has an extraordinarily high affinity (affinity constant > 1015 M-1) for biotin. This high affinity assures the user of a rapidly formed and stable complex between avidin and the biotin-labeled probes. The protein streptavidin, produced by the bacterium Streptomyces avidinii, has a structure very similar to avidin, and also binds biotin tightly. It often exhibits lower non-specific binding, and thus is frequently used in place of avidin. Once a biotin-avidin complex forms, the bond is essentially irreversible. The biotin-avidin system is widely used and has proven to be very useful in the detection and localization of antigens, glycoconjugates, and nucleic acids by employing biotinylated antibodies, lectins, or nucleic acid probes. As said, a reactive group with such a small size is advantageous for achieving a close distance between a dye pair. Biotin is a vitamin with a molecular weight of only 244 daltons. Furthermore, many biotin molecules can be coupled to a protein, enabling a biotinylated probe to bind more than one molecule of avidin. Avidin, streptavidin and biotin are available from many commercial sources. Various standard procedures for preparing biotin-conjugates are known to those skilled in the art, most of which can be completed within a day. Moreover, commercial biotinylation kits are available which contain all the necessary components for protein biotinylation.
- If a set of probes is used wherein each probe is provided with a different reactive group, a suitable substance comprises a molecule capable of binding at least one of each reactive group. Alternatively, such a binding substance comprises a complex of at least two molecules that can be covalently or non-covalently attached to each other, wherein each molecule is capable of binding to a reactive group.
- A method according to the invention allows detection of at least two interacting molecules in a cell wherein at least one of said molecules is a proteinaceous substance. In another embodiment, at least one of said molecules is a nucleic acid. In yet another embodiment of the invention, at least one of said molecules is a lipid or a carbohydrate. For example, the invention provides a method to detect the interaction of at least one protein with at least one nucleic acid, such as a DNA-binding protein binding to a specific DNA conformational sequence. The family of DNA-binding molecules includes transcriptional activators or repressor proteins as well as other proteins which bind to double- and / or single- stranded DNA. It also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases. In one embodiment of the invention, a method provided is applied to detect an interaction between a RNA-binding protein and a RNA molecule. RNA-binding proteins are required for translation regulation of gene expression. They are involved in multiple post-translational processes such as the regulation of pre-mRNA splicing, mRNA stability and transport of RNAs between nucleus and cytoplasm. For example, a probe may be used which binds to an RNA-binding protein, like an antibody against a certain splicing factor, in combination with a second probe which recognizes a specific RNA sequence.
- A FRET signal is produced only when an interaction takes place between the splicing factor and the RNA. The method provided permits detection of a protein-nucleic acid interaction at the single cell level. To avoid interference with an interaction between molecules of interest, it is preferred that the binding domains of the probes recognize and bind to a region of the molecules of interest that is distinct from the site of interaction between said molecules.
- In another embodiment, probes are provided which can detect the interaction between a protein, such as a carbohydrate binding protein (CBP), and a carbohydrate. Protein-carbohydrate interactions are now recognized to be important mediators of cell communication. In the last decade many novel CBPs have been described, and several have been documented to play critical roles in cell trafficking and cell signalling. CBPs recognize carbohydrate ligands on glycoproteins and glycolipids. Included are four large families of CBPs, the siglecs, C-type lectins, galectins and the subset of T cell antigen receptors (TCR) that recognize carbohydrate ligands presented by CD1 and MHC antigen presenting molecules.
- In another aspect, the present invention concerns a probe set that can be used for the detection of a protein-lipid interaction, at least one probe being reactive with a protein of interest and at least one probe being reactive with a lipid of interest. The protein may be an enzyme, such as a lipase, a lipid kinase or a lipid phosphatase, interacting with a lipid substrate. The protein probe may comprise an antibody specifically reactive with said protein. A lipid probe according to the invention can be a protein moiety with lipid binding properties. Particularly interesting are those lipid probes which specifically recognize and bind to a lipid molecule which is involved in signal transduction pathways, like phosphoinositide polyphosphates or lipid second messengers diacylglycerol (DAG) or phosphatidic acid (PA). Chimeric green fluorescent protein -pleckstrin homology (PH) domain proteins have been used as a molecular sensor to visualize phosphoinositide polyphosphates (PtdInsP(n)) in living cells. A suitable lipid probe includes a recombinantly produced and purified PH domain. Also included are the DAG-binding domain of protein kinase C (PKC) and the PA -binding region of Raf-1 kinase. A lipid probe comprises an antibody directed against a specific lipid, like a monoclonal antibody specifically reactive with PtdInsP(3).10 But other lipid probes can be thought of as well.
- A set of dye-conjugated probes according to the invention can be used to detect a wide variety of various signal transduction events, either stable or transient, at the single cell level. These include the interaction of a receptor with one or more other molecules, like receptor-ligand interaction, receptor clustering or multimerization, the interaction of a receptor with an intracellular signalling molecule. Other events to be detected using a method provided herein comprise interaction of various signalling molecules with each other, like the docking of a Src-homology 2 (SH2)-containing protein to a specific phosphotyrosine residue in another protein, or the binding of a Src-homology 3 (SH3 )-containing protein to proline-rich stretch in another protein. Using specific probes the present method permits to detect interactions between cytoskeletal proteins as well as between nuclear proteins (in the so-called signalosome). Activation of a signal transduction pathway often includes protein phosphorylation by tyrosine kinases and/or serine/threonine kinases. Protein phosphorylations can change enzyme activities and protein conformations. The eventual outcome is an alteration in cellular activity and changes in the program of genes expressed within the responding cells.
- In another embodiment, a probe comprises a phospho-specific antibody which specifically recognizes a protein in its phosphorylated state. A phosphorylated residue may be a tyrosine, serine or threonine residue. Phosphospecific antibodies against a wide variety of signalling proteins can be obtained from a number of companies such as Upstate Biotechnology, New England Biolabs, Sigma and many others. For example, a Cy3-labeled phosphotyrosine-specific antibody against the Erb receptor tyrosine kinase can be used to specifically detect the activated form of the receptor. Other examples of suitable probes include a phosphospecific antibody that recognizes only the phosphorylated form of the nuclear transcription factor forkhead in rhabdomyosarcoma (FKHR), protein kinase B (PKB), mitogen-activated protein kinase (MAPK). For several years, analogs of nucleotides that serve as substrates or inhibitors of enzymes, and derivatives that selectively bind to regulatory sites of nucleotide-binding proteins have been used as structural and mechanistic probes for isolated proteins. These type of molecules also represent interesting probes for practicing a method according to the invention.
- A method provided herein allows detection of interacting molecules at the single cell level. Single cells can be analysed using e.g. flow cytometry or fluorescence microscopy. In a preferred embodiment, said detection is performed by flow cytometry. A major advantage of flow cytometry is that it directly gives quantitative data and that it is very rapid (results can be obtained within a few hours). Detecting energy transfer by flow cytometry allows high throughput analysis of interacting molecules. High throughput flow cytometric detection of molecular interactions at the single cell level allows for time course and dose response studies of one or more of the afore mentioned interactions, such as signal transduction events, transcription factor interactions. For example, the interaction between the Tcf-1 transcription factor with beta-catenin, or the association of the cytosolic protein tyrosine kinase ZAP-70 with the CD3-zeta chain of the T-cell receptor (TCR), can now be studied at the single cell level using a set of suitable probes according to the invention. In one embodiment, a method provided allows the detection of molecular interaction at the single cell level in permeabilized and / or fixed cells. Furthermore, because the method provided can detect endogenous molecules, it is especially useful to investigate molecular interactions in primary cells. It can for example be used to discriminate between normal and abnormal cells on the basis of one or more of the above-mentioned interactions. Thus, the current invention is preferably practiced with a donor / acceptor pair that is suitable for FRET detection by flow cytometry. A pair commonly used for FRET includes fluorescein isothiocyanate (FITC) and tetramethylrhodamine isothiocyanate (TRITC). However, the sensitivity is poor because of the relatively low molar extinction coefficient and low quantum yield for FITC and TRITC. In addition, laser sources for this pair are usually not found on standard flow cytometers. These problems are not encountered when using the R-phycoerythrin (R-PE) / Allophycocyanin (APC) pair. These dyes are large protein complexes that contain multiple chains and chromophores that are linked covalently. They belong to the group of phycobiliproteins. Phycobiliproteins are produced naturally and are associated with phycobilisomes and are used by different cyanobacteria or algea. The PE/APC pair is very promising because 90% of FRET efficiency may be reached in spite of the sizes of PE and APC. Furthermore, this FRET pair can be detected easily on commercially available flow cytometers such as FACSCalibur, LSR, and FACSVantage equipped with two common lasers (or a diode) in a configuration emitting at 488 and 632 nm.
- Detection of energy transfer using flow cytometry or fluorescence activated cell sorting (FACS) offers the possibility to perform rapid, multiparametric analysis of specific individual cells in a heterogeneous population. The detection of multiple fluorescent markers on a cell by flow cytometry provides a powerful tool for single cell analysis and allows subset gating of a target cell population. Selective analysis within a target cell population increases sensitivity of the detection method.
- For the detection of molecular interactions in primary cells, it is especially advantageous to use an additional marker to define a target cell population of interest. A number of important biological applications in infectious diseases, minimal residual disease detection and monitoring, and gene therapy typically require the analysis and isolation of rare cells (e.g. hematopoietic stem/progenitor cells) from a large background. A method according to the invention can include intracellular staining or staining of a surface marker to define a target cell population in a mixture of cells comprising staining with a fluorescent marker antibody capable of selectively identifying said cellular marker. The present method now allows gating of subset of cells that are present in a mixture of cells via immunophenotypic characteristics, i.e. it permits the detection of a interacting molecules in a rare population of cells.
- In a preferred embodiment, a method is provided to identify and/ or isolate rare single cells using multiparameter flow cytometry/cell sorting techniques and to characterize molecular interaction at the single-cell level. A method provided now allows detection of interacting molecules in a mixture of abnormal cells with normal cells to identify and quantitate abnormal cells based on the basis of an aberrant interaction between molecules. Such a method is particularly suited for application to a number of important problems in immune system development, infectious diseases, cancer and gene therapy. Typically, prior to staining a cell sample with a probe set, cell are labeled with at least one relevant dye-conjugated antibody according to standard procedures in order to define a target cell population in a mixture of cells. A mixture of cells comprises living cells. It also comprises permeabilized and / or fixed cells. A method is provided comprising staining a sample for at least one cellular marker to define a target cell population comprising contacting said sample with a compound capable of selectively binding to a cellular marker. In a preferred embodiment, such a compound is directly tagged with a fluorescent dye. A suitable compound comprises a fluorescently labelled antibody or a binding fragment functionally equivalent thereto. Also, a compound capable of selectively binding to a cellular marker can be used which can be detected using a dye-conjugated secondary reagent (e.g. a fluorescently labelled secondary antibody). A cellular marker comprises any kind of intracellular or membrane-bound marker which can be used to distinguish a subpopulation of cells in a mixture of cells. A cellular marker can be a cluster of differentiation (CD) antigen. CD markers are cell surface molecules of among others haemopoietic cells that are distinguishable with monoclonal antibodies. Haemopoietic cells comprise thymocytes, dendritic cells, Langerhans' cells, neutrophils, eosinophils, germinal centre B cells, follicular dendritic cells, plasma cells and bone-marrow cells. For example, suitable cellular markers comprise CD1, CD3, CD4, CD8, CD10, CD19, CD20, CD33, CD34 and CD117. Monoclonal antibodies directed against a large number of human CD markers can be obtained from various suppliers, such as BD Biosciences or Ancell Immunology Research Products, Bayport, USA. Often, antibodies are available that are directly conjugated with a fluorochrome of choice e.g. CD10-PE or CD19-FITC, which is obviously the preferred choice to practice a method according to the invention.
- The choice of dye should preferably but not exclusively aim at the usage of two or three dyes for immunophenotyping in addition to the FRET dyes for detection of close interaction of at least two molecules. For example, a FRET probe set according to the invention can be combined with one or more dyes to mediate leukocyte subset gating via immunophenotypic characteristics, e.g. CD10, CD19 and CD20 to accurately define subsets of precursor-B-cells in bone marrow, or CD1, CD4 and CD8 to define subsets of thymocytes, or CD34 and/or CD117 to identify stem/precursor cell populations.
- In one embodiment, the invention provides a method for detecting at least two interacting intracellular molecules using of a set of probes according to the invention, each probe being reactive with a different molecule comprising providing a sample comprising a cell, whereby said sample will be subject to fixation and permeabilization, contacting said preparation with a set of probes each probe capable of binding to a specific molecule under conditions that allow juxtaposing of said probes on said molecules, removing any unbound and any non-specifically bound probe and detecting juxtaposition of said probes via FRET. The sample is preferably treated so as to obtain a preservation of the morphology of the material and permeabilization in order to ensure sufficient accessibility of a molecule of interest to a probe. The type of treatment will depend on several factors, for instance on the fixative used, the extent of fixation and the type and properties of the molecules of interest. Fixation may be carried out with a fixative such as formaldehyde. In a preferred embodiment, the method is practiced to detect intracellular molecules that are positioned within a very short distance of each other, for example within 100 Ångstrom, preferably within 50 Ångstrom, more preferably within 20 Ångstrom.
- A method is provided wherein a sample comprises a primary cell that is obtained from a biological sample. A biological sample can be a body fluid sample including blood, bone marrow, urine, cerebrospinal fluid (CSF), saliva. It may also be a tissue sample or a tissue homogenate. A sample comprises a cultured cell which may be a cultured primary cell, for example a cultured dermal fibroblast obtained from a skin biopsy. Furthermore, a sample may comprise a cultured cell from an established laboratory cell line, like a HeLa, COS, MCF-7 or a Jurkat cell line, which can be obtained from a number of sources such as the American Type Culture Collection (ATCC; see www.atcc.org for an online catalog).
- The invention provides a method to prepare a probe set, comprising contacting each probe with a suitable dye or a derivative thereof to form a conjugate between said probe and said dye and purifying said conjugate from excess dye further comprising contacting at least one probe with a suitable reactive group or a derivative thereof to form a conjugate between said probe and said reactive group and purifying said conjugate from excess reactive group. As discussed above, a probe may comprise a conventional (poly- or monoclonal) or a synthetic antibody or other binding molecule, a nucleic acid binding probe, a peptide nucleic acid probe capable of hybridising to a specific nucleic acid sequence, a lipid binding molecule, a carbohydrate binding molecule. The present invention is advantageously carried out using probes with minimal negative steric effects on energy transfer efficiency between dyes attached to the probes. For example, an antibody probe smaller than a complete IgG, such as a Fab', Fab, a single chain Fv fragment or a diabody (scFv dimer) may advantageously be used. Furthermore, a low molecular weight fluorescent FRET pair can be used. Perhaps the most convenient and widely used functional group for the labelling of biological molecules is a primary amino group. This can be provided by the epsilon-amino group of a lysine residue, or the free N-terminus of a peptide / protein. Alternatively, it is possible to introduce primary amine containing modifier groups during automated synthesis of, for example, oligonucleotides. Stable active esters of fluor labelling species that may be stored as solid materials, in particular N-hydroxysuccinimide (NHS) esters have been extensively used over many years for the acylation of such amino groups. As an alternative to primary amino labelling, thiol containing groups such as those contained in cysteine residues or, as with primary amino groups, those introduced as modifiers during automated synthesis (of for example oligonucleotides) can be specifically targeted by maleimide labelling reagents (for example of Cy3 and Cy5). It is not always feasible to consider the use of either primary amino or thiol labelling on all biological molecules. A further common route for labelling of, for example, carbohydrate species is via an aldehyde group targeted by hydrazide labelling reagents.
- A commercial kit may suitably be used for obtaining a probe set comprising at least two probes, each probe provided with a dye and additionally provided with a reactive group. Typically, labelling and purifying probe conjugates with such labelling kits can be readily accomplished in under three hours, with very little hands-on time. For example, there is a kit available for labelling a proteinaceous probe, e.g. an antibody or a peptide, with a fluorescent dye (www.probes.com/handbook/tables/1570.html). The amount of dye necessary for the desired proteinaceous sample is calculated using the guidelines outlined in the kit's protocol. Generally, a reactive dye has a succinimidyl ester moiety that reacts efficiently with primary amines of a proteinaceous substance to form a stable dye-conjugate. Purification of a conjugate can be easily accomplished using a spin column or a size-exclusion spin column. The final coupling ratio can be determined according to standard procedures known to those skilled in the art. A dye to protein ration of approximately 2.5 to 1 often results in the retention of the ability of the probe to specifically recognize a molecule and in sufficient fluorescence for use of the FRET technique. Likewise, various commercial kits are available which can be used for labelling a probe with a reactive group, such as biotin. The biotin-XX sulfosuccinimidyl ester (SSE) is water soluble and reacts with a primary amine to form a stable biotin conjugate. The biotin-XX SSE has a 14-atom spacer that enhances the binding of biotin derivatives to avidin's relatively deep binding sites. A labelling kit typically contains a ready-to-use spin column for purification of a biotinylated probe from excess reagents.
The invention also provides a diagnostic test kit for the determination of interacting molecules in a biological sample comprising a set of probes according to the invention. In a preferred embodiment, the test kit provided comprising a probe set for FRET-mediated detection of interacting molecules is combined with one or more dye-conjugated antibodies that can be used for defining a target cell population within a mixture of cells. This is generally advantageous when the sample comprises a biological sample. For example, it permits identification and quantification of abnormal cells in a mixture of abnormal cells with normal cells, e.g. on the basis of defined abnormal signalling complexes. Many different types of abnormal signaling complexes can be detected in diagnostic applications using a method according to the invention. For example, the interaction of the RAG1 and RAG2 proteins in lymphoid leukemias that have ongoing rearrangements can be evaluated. Only in those cells where RAG1 and RAG2 dimers are tethered to the target DNA sequence, rearrangements are in progress. Another example involves the detection of an interaction of dephosphorylated beta-catenin with a member of the TCF family of transcription factors. Only in those cells where after cellular activation a signal is detected, the TCF factors are transcriptionally active. Thus, a method as provided herein provides means for monitoring, optionally at the single cell level, normal and pathological Wnt signaling, e.g. in colon carcinomas, melanomas, prostate cancer, breast cancer etc. - Furthermore, a method or a probe set of the invention is advantageously used in the area of drug discovery, e.g. to select a (candidate) drug compound from among a library of compounds. Following drug target identification, biopharmaceutical companies need a rapid system for screening the target against libraries of compounds to identify those compounds that will have an effect on the target and that demonstrate the potential to become effective drugs. In one embodiment, a FRET based method of the invention is used to screen for compounds which affect the interaction between two or more molecules in a cell, e.g. compounds that can stimulate or inhibit the formation of signaling complexes such as the signalosome. Hereto, a probe set is used comprising a first probe that is reactive with a first protein of the signaling complex and a second probe that is reactive with a second protein protein of the complex. When the complex is intact, the first and second protein interact such that the dye-conjugated probes are juxtaposed and a FRET signal can be detected. Upon addition of a compound (e.g. a drug candidate molecule) which binds to a component of the complex, the interaction between proteins within the complex is disrupted. As a result, the protein-bound probes are no longer juxtaposed and FRET no longer occurs. Of course, a similar approach can be undertaken to screen for compounds which stimulate or enhance an interaction between molecules. In that case, no FRET signal is detected in the absence of the compound but addition of the compound brings two or more molecules in close proximity of each other such that FRET occurs. In another embodiment, a method as provided herein is used to detect the interaction between a compound (drug) and its target, i.e. the interacting molecules are the compound and the target. This requires a set of probes wherein one probe is reactive with the compound and another probe that is reactive with the target (protein), for instance a compound-specific antibody probe and a target-specific antibody probe may be used. It can be imagined that the development of specific antibodies for hundreds of different compounds to be screened is not very attractive in e.g. a high throughput screening setting. However, one may provide different compounds with an identical (epitope) tag such that only one (antibody) probe directed against the tag can be used together with a target-specific probe for detecting the interaction between the compound and its target.
-
-
Figure 1 . Schematic diagram of the principle of fluorescence resonance energy transfer (FRET) with fluorochrome X as donor dye and Y as acceptor dye.- A. The acceptor dye Y will not be excitated by the emission light of the donor dye X, if the distance between X and Y is too large. B. If the distance between the donor and acceptor dye is sufficiently small (< 80 Ångstrom but preferably < 50 Ångstrom), the emission light of the donor dye X will excitate the acceptor dye Y.
-
Figure 2 . Schematic drawing of the closely interacting proteins A and B recognized by a anti-A and an anti-B antibody.- A. Probe A is conjugated with donor dye X and probe B with acceptor dye Y. Furthermore, both probes are conjugated with biotin. B. After incubation with probes A en B, the probes can be bound together via incubation with avidin, provided that the probes indeed recognize and bind to the closely interacting proteins A and B. This juxtaposition of the two antibody probes (stabilized by the biotin-avidin system) is detectable via the FRET principle (see
Figure 1 ).
- A. Probe A is conjugated with donor dye X and probe B with acceptor dye Y. Furthermore, both probes are conjugated with biotin. B. After incubation with probes A en B, the probes can be bound together via incubation with avidin, provided that the probes indeed recognize and bind to the closely interacting proteins A and B. This juxtaposition of the two antibody probes (stabilized by the biotin-avidin system) is detectable via the FRET principle (see
- The invention provides a method for the detection of interacting proteins and other molecules using a set of at least a first and a second probe each probe provided with a dye wherein said dyes together allow energy transfer; at least said probes being provided with a reactive group wherein said reactive group allows to modulate juxtaposing of said probes such that there is an increased likelihood of energy transfer between them. Preferably, yet not exclusively, a probe set according to the invention comprises a set of two dye-conjugated antibodies, each antibody additionally provided with a reactive group. To exemplify the invention, we will describe the preparation of such a set of probes.
- Methods of producing an antibody are known to those skilled in the art, e.g. using hybridoma technology or phage display. To obtain a polyclonal antibody, a laboratory animal is immunized with an immunogen such as a recombinant protein or a synthetic peptide. The animal's immune response is monitored by taking test bleeds and determining the titer of the reactivity. When appropriately high titers are obtained, blood is collected from the animal and antisera are prepared. Further fractionation of the antisera to enrich for antibodies reactive to the protein can be done if desired. See e.g. Harlow et al. Antibodies. A Laboratory Manual, Cold Spring Harbor Publications, New York (1988). Monoclonal antibodies can be obtained by various techniques familiar to those skilled in the art. Antibodies obtained can be characterised conventional immunodiagnostic techniques e.g. by Western blotting using lysates of cells expressing a recombinant fusion protein or by ELISA.
- Biotin is typically conjugated to proteins via primary amines (i.e., lysines). Usually, between 3 and 6 biotin molecules are conjugated to each antibody. Dialyze or exchange over a column the antibody in 100 mM carbonate, pH 8.4. Measure the antibody concentration after buffer equilibration. (For IgG, 1 mg/ml has an A(280) of 1.4). If the antibody concentration is less than 1 mg/ml, the conjugation will probably be sub-optimal. If necessary, dilute the antibody to a concentration of 4 mg/ml. Dissolve 10 mgs of Biotin (N-hydroxysuccinimidobiotin, Pierce) in 1 ml anhydrous DMSO (anhydrous dimethyl sulfoxide, Aldrich) immediately before use. The reactive biotin molecule is unstable. Once the biotin is solubilized, it should be used immediately. Add Biotin to give a ratio of 80 µg per mg of antibody; mix immediately. Wrap the tube in foil; incubate and rotate at room temperature for 2 hours. Remove the unreacted Biotin and exchange the antibody into 10 mM Tris pH 8.2, 150 mM NaCl, pHix (5 mg/ml pentachlorophenol in 95% ethanol (use as 10,000x, or 3-4 drops per liter) Sigma).
- As discussed before, a large variety of dyes or fluorochromes can be used to label a probe according to the present invention. As an example, Cy5 conjugation of an antibody probe is given but of course many other fluorochromes can chosen. The entire conjugation can typically be performed in about a half-day. The reactive Cy5 molecule is unstable. Open a vial, and weigh out the amount you need (typically, 1 or 2 mg is more than enough). Reseal the vial and store under desiccant at 4 degrees Celsius. Immediately dissolve the Cy5 in DMSO at a concentration of 10 mg/ml.
- Dialyze or exchange over a column the antibody in 500 mM carbonate, pH 9.5. Measure the antibody concentration after buffer equilibration. (For IgG, 1 mg/ml has an A(280) of 1.4). If the antibody concentration is less than 1 mg/ml, the conjugation will probably be sub-optimal. If necessary, dilute the antibody to a concentration of 4 mg/ml.
- Cy5 is covalently coupled to primary amines (lysines) of the immunoglobulin. Dissolve the Cy5 (Cy5-bis-OSU, N,N'-biscarboxypentyl-5,5'-disulfonato-indodicarbocyanine, Amersham Life Science) in anhydrous DMSO (dimethyl sulfoxide, Aldrich) immediately before use, at a concentration of 10 mg/ml. Do not delay between weighing out the Cy5 and dissolving it in DMSO; likewise, do not delay the addition of the solubilized material to the antibody. For the optimal ratio of 5:1, add 40 µg Cy5 per mg of antibody; mix immediately. Wrap the tube in foil; incubate and rotate at room temperature for 1 hour. Remove the unreacted Cy5 and exchange the antibody into 10 mM Tris pH 8.2, 150 mM NaCl, pHix (Sigma; 5 mg/ml pentachlorophenol in 95% ethanol (use as 10,000x, or 3-4 drops per liter), by gel filtration or dialysis.
-
- 1. Mason DY, Comans-Bitter WM, Cordell JL, et al, Antibody L26 recognizes an intracellular epitope on the B-cell-associated CD20 antigen. Am J Pathol 1990; 136: 1215-22.
- 2. Matyus L, Fluorescence resonance energy transfer measurements on cell surfaces. A spectroscopic tool for determining protein interactions. J Photochem Photobiol B 1992; 12: 323-37.
- 3. Chan FK, Siegel RM, Zacharias D, et al, Fluorescence resonance energy transfer analysis of cell surface receptor interactions and signalling using spectral variants of the green fluorescent protein. Cytometry 2001; 44: 361-8.
- 4. Siegel RM, Chan FK, Zacharias DA, et al, Measurement of molecular interactions in living cells by fluorescence resonance energy transfer between variants of the green fluorescent protein. Sci STKE 2000; 2000: L1.
- 5. Wouters FS, Bastiaens PI. Fluorescence lifetime imaging of receptor tyrosine kinase activity in cells. Curr Biol 1999; 9:1127
- 6. Guo C, Dower SK, Holowka D, Baird B. Fluorescence resonance energy transfer reveals interleukin (IL)-1-dependent aggregation of IL-1 type I receptors that correlates with receptor activation. J Biol Chem 1995; 270:27562
- 7. Broudy VC, Lin NL, Buhring HJ, et al, Analysis of c-kit receptor dimerization by fluorescence resonance energy transfer. Blood 1998; 91: 898-906.
- 8. Szollosi J, Damjanovich S, Matyus L, Application of fluorescence resonance energy transfer in the clinical laboratory: Routine and research. Cytometry 1998; 34:159
- 9. Tanke, HJ. Fluorochromen voor twee- en drievoudige labelingen. Immunofenotypering in de diagnostiek: indicatiestellingen, uitvoering en interpretatie. Eds. Van Dongen, Groeneveld, Adriaansen, Hooijkaas (ISBN 90-73436-16-8). 1994; pages 55-61.
- 10. Chen R, Kang VH, Chen J, et al, A monoclonal antibody to visualize PtdIns(3,4,5)P(3) in cells. J Histochem Cytochem. 2002 ; 50(5):697
Claims (18)
- A set of at least a first and a second molecular probe, each probe provided with a dye wherein said dyes together allow energy transfer, each probe comprising a binding domain capable of specifically binding to a molecule of interest, and wherein said probes are additionally provided with a reactive group capable of specific binding to a bridging substance allowing juxtaposing said at least first and second probe following binding to said molecule of interest and wherein said reactive group is not involved in binding to the molecule of interest.
- A set according to claim 1 wherein said reactive group allows juxtaposing said dyes within a distance of 10 nanometer (100 Ångstrom) of each other, preferably within a distance of 5 nanometer_(50 Ångstrom) of each other, more preferably within a distance of 2 nanometer (20 Ångstrom) of each other.
- A set according to claim 1 or 2 wherein a reactive group of said first probe is not directly reactive with said second probe.
- A set according to anyone of claims 1 to 3 wherein at least one probe is provided with a multiplicity of said reactive groups.
- A set according to anyone of claims 1 to 4 wherein said probe is an antibody or a binding fragment functionally equivalent thereto.
- A set according to anyone of claims 1 to 5 wherein at least one probe is a nucleic acid.
- A set according to anyone of claims 1 to 6 wherein at least one of said dyes is a fluorochrome.
- A set according to claim 7 wherein said fluorochrome is selected from the group consisting of fluorescein isothiocyanate (FITC), tetramethylrhodamine isothiocyanate (TRITC), Texas Red (TR), R-phycoerythrin (R-PE), allophycocyanin (APC), members of the phycobiliproteins, Cy3, Cy5, Cy 5.5, Cy7, cyanine dyes, Alexa Fluor dyes, tandem conjugates thereof, and quantum dot dyes.
- A set according to anyone of claims 1 to 8 wherein said reactive group is biotin.
- An in vitro method for detecting at least two interacting molecules in a cell using a set of at least a first and a second molecular probe, each probe provided with a dye wherein said dyes together allow energy transfer and each probe comprising a binding domain capable of specifically binding to a different molecule of interest, wherein said probes are additionally provided with a reactive group that is not involved in binding to a molecule of interest and capable of specific binding to a bridging substance, allowing for juxtaposing said at least first and second probe following binding to said molecule of interest such that there is an increased likelihood of energy transfer between said dyes, wherein a reactive group of said first probe is not directly reactive with said second probe, comprising:providing a set of probesproviding a sample comprising a cell-contacting said sample with said set of probes-under conditions that allow juxtaposing said probes on said interacting molecules-contacting said probes with a substance capable of linking at least a reactive group of said first probe to said second probe, and-detecting juxtaposition of said probes via FRET to detect said interacting molecules.
- A method according to claim 10 wherein said substance allows juxtaposing said dyes within a distance of 0.2-10 nanometer (2 to 100 Ångstrom) of each other.
- A method according to claim 10 or 11 wherein said reactive group comprises biotin and wherein said substance comprises avidin or streptavidin.
- A method according to anyone of claim 10 to 12 including staining said sample for at least one cellular marker to define a target cell population comprising contacting said sample with a compound capable of selectively binding to said cellular marker, wherein said cellular marker is preferably a cluster of differentiation (CD) antigen.
- A method according to anyone of claims 10 to 13 wherein at least one of said molecules is a proteinaceous substance, a nucleic acid, a lipid molecule, or a carbohydrate.
- A method according to anyone of claims 10 to 14 allowing detection at the single cell level, preferably using comprises flow cytometry.
- A diagnostic kit comprising a set of probes according to anyone of claims 1 to 9.
- A kit according to claim 16, additionally comprising the bridging substance.
- Use of a probe set according to anyone of claims 1 to 9 or a method according to anyone of claims 10 to 15 to screen for a compound which affects the interaction between two or more molecules in a cell.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03776064A EP1561114B1 (en) | 2002-11-07 | 2003-11-06 | Fret probes and methods for detecting interacting molecules |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02079667 | 2002-11-07 | ||
EP02079667 | 2002-11-07 | ||
PCT/NL2003/000777 WO2004042404A1 (en) | 2002-11-07 | 2003-11-06 | Fret probes and methods for detecting interacting molecules |
EP03776064A EP1561114B1 (en) | 2002-11-07 | 2003-11-06 | Fret probes and methods for detecting interacting molecules |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1561114A1 EP1561114A1 (en) | 2005-08-10 |
EP1561114B1 true EP1561114B1 (en) | 2008-05-07 |
Family
ID=32309414
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03776064A Expired - Lifetime EP1561114B1 (en) | 2002-11-07 | 2003-11-06 | Fret probes and methods for detecting interacting molecules |
Country Status (11)
Country | Link |
---|---|
US (1) | US7413862B2 (en) |
EP (1) | EP1561114B1 (en) |
JP (1) | JP4511363B2 (en) |
CN (1) | CN1735808A (en) |
AT (1) | ATE394677T1 (en) |
AU (1) | AU2003283860B2 (en) |
CA (1) | CA2505515C (en) |
DE (1) | DE60320828D1 (en) |
ES (1) | ES2306900T3 (en) |
NZ (1) | NZ540219A (en) |
WO (1) | WO2004042404A1 (en) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004042404A1 (en) | 2002-11-07 | 2004-05-21 | Erasmus Universiteit Rotterdam | Fret probes and methods for detecting interacting molecules |
EP1634603A1 (en) * | 2004-08-26 | 2006-03-15 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Treatment of transformed or infected biologic Cells |
KR100704011B1 (en) | 2005-02-16 | 2007-04-04 | 한국과학기술원 | Detection method for specific biomolecular interactions using FRET between metal nanoparticle and quantum dot |
JP4639935B2 (en) * | 2005-05-09 | 2011-02-23 | ソニー株式会社 | Surface for detecting interaction between substances, DNA chip or other sensor chip, probe, and method for reducing background noise fluorescence |
JP5085320B2 (en) | 2005-05-24 | 2012-11-28 | 美穂 鈴木 | Multiple simultaneous analysis methods for biological reactions or in vivo state changes |
WO2007062466A1 (en) | 2005-11-29 | 2007-06-07 | The University Of Sydney | Demibodies: dimerisation-activated therapeutic agents |
KR100878980B1 (en) | 2005-12-31 | 2009-01-14 | 성균관대학교산학협력단 | Novel FRET system consisting of a QD donor and a dye accepotor attached to DNA |
WO2007125822A1 (en) * | 2006-04-28 | 2007-11-08 | Tokyo Institute Of Technology | Complex for use in the screening of substance |
DK2064348T3 (en) * | 2006-09-18 | 2012-05-29 | Ensemble Therapeutics Corp | Receptor family profiling |
EP2174115B1 (en) * | 2007-07-09 | 2013-08-28 | Fio Corporation | Systems and methods for enhancing fluorescent detection of target molecules in a test sample |
WO2009021026A1 (en) * | 2007-08-06 | 2009-02-12 | University Of Kentucky Research Foundation | Semi-synthetic antibodies as recognition elements |
WO2009067009A1 (en) * | 2007-11-21 | 2009-05-28 | Erasmus University Medical Center Rotterdam | Improved fret-probes and use thereof |
US8180421B2 (en) * | 2007-12-12 | 2012-05-15 | Kimberly-Clark Worldwide, Inc. | Resonance energy transfer based detection of nosocomial infection |
US8431356B2 (en) | 2009-01-22 | 2013-04-30 | Regents Of The University Of Minnesota | Fluorescence resonance energy transfer assays for sarco/endoplasmic reticulum calcium atpase and phospholamban |
EP2211178A1 (en) * | 2009-01-22 | 2010-07-28 | Universität Potsdam | Method for detecting an analyte in a sample by multiplexing FRET analysis and kit |
CN101638579B (en) * | 2009-08-21 | 2013-03-06 | 天津城市建设学院 | Quantum dot-cyanine dye-folic acid biological probe and preparation method thereof |
DE102010010052A1 (en) * | 2010-03-03 | 2011-09-08 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Signaling binding molecules, devices and methods for their use |
WO2012014778A1 (en) * | 2010-07-26 | 2012-02-02 | オリンパス株式会社 | Method for detecting dilute particles in solution using luminescent probe |
CN103221806B (en) | 2010-09-10 | 2015-11-25 | 奥林巴斯株式会社 | Use the optical analysis method of the measurement of the light of plural wavelength band |
EP2602613B1 (en) | 2010-09-10 | 2017-02-22 | Olympus Corporation | Optical analysis method using optical intensity of single light-emitting particle |
JP5907882B2 (en) | 2010-10-19 | 2016-04-26 | オリンパス株式会社 | Optical analyzer for observing polarization characteristics of single luminescent particles, optical analysis method, and computer program for optical analysis therefor |
CN103229042B (en) | 2010-11-25 | 2016-06-29 | 奥林巴斯株式会社 | The light analytical equipment and the light that utilize the wavelength characteristic of the light of single incandescnet particle analyze method |
US8569254B2 (en) | 2010-12-10 | 2013-10-29 | National Yang Ming University | Methods for modulating the expression and aggregation of CAG-expanded gene product in cells and methods for identifying agents useful for doing the same |
WO2012099234A1 (en) | 2011-01-20 | 2012-07-26 | オリンパス株式会社 | Photoanalysis method and photoanalysis device using detection of light from single light-emitting particle |
CN103339256B (en) | 2011-01-26 | 2016-03-16 | 奥林巴斯株式会社 | Differentiate the method for polymorphic nucleic acid molecule |
JP5856984B2 (en) | 2011-01-26 | 2016-02-10 | オリンパス株式会社 | Nucleic acid molecule polymorphism identification method |
JP5904996B2 (en) | 2011-03-29 | 2016-04-20 | オリンパス株式会社 | Optical analyzer using single luminescent particle detection, optical analysis method, and computer program for optical analysis |
CN103477210B (en) | 2011-04-13 | 2015-09-23 | 奥林巴斯株式会社 | The light analytical equipment utilizing single incandescnet particle to detect, light analytical approach and light analysis computer program |
EP2700935A4 (en) | 2011-04-18 | 2014-10-22 | Olympus Corp | Quantitative determination method for target particles, photometric analysis device, and computer program for photometric analysis |
WO2013021687A1 (en) | 2011-08-11 | 2013-02-14 | オリンパス株式会社 | Method for detecting target particles |
EP2746748B1 (en) | 2011-08-15 | 2017-12-06 | Olympus Corporation | Photometric analysis device using single light emitting particle detection, photometric analysis method and computer program for photometric analysis, |
JP6010033B2 (en) | 2011-08-26 | 2016-10-19 | オリンパス株式会社 | Single particle detection apparatus using optical analysis, single particle detection method, and computer program for single particle detection |
CN103765196B (en) | 2011-08-26 | 2016-03-02 | 奥林巴斯株式会社 | The light analytical equipment utilizing single incandescnet particle to detect and light analytical approach |
CN103765194B (en) | 2011-08-30 | 2016-02-17 | 奥林巴斯株式会社 | The detection method of intended particle |
JP6010035B2 (en) | 2011-08-30 | 2016-10-19 | オリンパス株式会社 | Optical analysis apparatus using single luminescent particle detection, optical analysis method, and computer program for optical analysis |
WO2013069504A1 (en) | 2011-11-10 | 2013-05-16 | オリンパス株式会社 | Spectroscopy device, spectroscopy method, and computer program for spectroscopy, employing individual light-emitting particle detection |
LT2802607T (en) * | 2012-01-13 | 2018-02-12 | Julius-Maximilians-Universität Würzburg | Dual antigen-induced bipartite functional complementation |
EP2816344A4 (en) | 2012-02-17 | 2015-09-23 | Olympus Corp | Optical analysis device using single particle detection technique, optical analysis method and computer program for optical analysis |
EP2818850B1 (en) | 2012-02-22 | 2016-08-03 | Olympus Corporation | Method for detecting a target particle |
JP6095645B2 (en) | 2012-03-21 | 2017-03-15 | オリンパス株式会社 | Method for detecting target nucleic acid molecule |
WO2013157283A1 (en) | 2012-04-18 | 2013-10-24 | オリンパス株式会社 | Method for detecting target particles |
CN104246479B (en) | 2012-04-18 | 2016-10-19 | 奥林巴斯株式会社 | Utilize single particle detection device, single particle detection method and the single particle detection computer program of light analysis |
EP3708189B1 (en) | 2013-07-05 | 2023-11-29 | University of Washington through its Center for Commercialization | Soluble mic neutralizing monoclonal antibody for treating cancer |
WO2015015951A1 (en) | 2013-07-31 | 2015-02-05 | オリンパス株式会社 | Optical microscope device, microscopy method, and computer program for microscopy using single-light-emitting-particle detection technology |
EP3059577A4 (en) | 2013-10-07 | 2017-05-31 | Olympus Corporation | Photometric analysis device employing single light-emitting particle detection, photometric analysis method, and computer program for photometric analysis |
US10281476B2 (en) | 2013-12-10 | 2019-05-07 | Regents Of The University Of Minnesota | Methods to identify modulators of RyR calcium channels |
US10794898B2 (en) | 2014-01-17 | 2020-10-06 | Regents Of The University Of Minnesota | High-throughput, high-precision methods for detecting protein structural changes in living cells |
CN104592396A (en) * | 2015-02-26 | 2015-05-06 | 南京大学 | Caspase-8 activity assay fluorescent probe based on fluorescence resonance energy transfer technology |
US10900070B2 (en) | 2015-05-01 | 2021-01-26 | The General Hospital Corporation | Multiplex analysis of gene expression in individual living cells |
IL274151B (en) | 2015-05-21 | 2022-07-01 | Harpoon Therapeutics Inc | Trispecific binding proteins and methods of use |
JPWO2017098597A1 (en) | 2015-12-09 | 2018-10-11 | オリンパス株式会社 | Optical analysis method and optical analysis apparatus using single luminescent particle detection |
WO2017132574A1 (en) * | 2016-01-29 | 2017-08-03 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for screening pediatric gliomas and methods of treatment thereof |
JP7101621B2 (en) | 2016-05-20 | 2022-07-15 | ハープーン セラピューティクス,インク. | Single domain serum albumin binding protein |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
MX2018014227A (en) | 2016-05-20 | 2019-08-22 | Harpoon Therapeutics Inc | Single chain variable fragment cd3 binding proteins. |
EA201991168A1 (en) | 2016-11-23 | 2019-12-30 | Харпун Терапьютикс, Инк. | PROTEIN BINDING PROSTATIC SPECIFIC MEMBRANE ANTIGEN |
KR20190087539A (en) | 2016-11-23 | 2019-07-24 | 하푼 테라퓨틱스, 인크. | PSMA-targeted triple specific proteins and methods of use |
EP3351926A1 (en) * | 2017-01-18 | 2018-07-25 | Hifibio | Method for analyzing and selecting a specific droplet among a plurality of droplets and associated apparatus |
US11535668B2 (en) | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
BR112019023855B1 (en) | 2017-05-12 | 2021-11-30 | Harpoon Therapeutics, Inc | MESOTHELIN BINDING PROTEINS |
CN115028727A (en) | 2017-05-12 | 2022-09-09 | 哈普恩治疗公司 | MSLN-targeting trispecific proteins and methods of use |
AU2018346955A1 (en) | 2017-10-13 | 2020-04-30 | Harpoon Therapeutics, Inc. | B cell maturation antigen binding proteins |
CN111630070A (en) | 2017-10-13 | 2020-09-04 | 哈普恩治疗公司 | Trispecific proteins and methods of use |
CA3114038A1 (en) | 2018-09-25 | 2020-04-02 | Harpoon Therapeutics, Inc. | Dll3 binding proteins and methods of use |
US11604186B2 (en) * | 2018-10-17 | 2023-03-14 | Molecular Devices (Austria) GmbH | Real time western blot assays utilizing fluorescence resonance energy transfer (FRET) |
US11726081B2 (en) | 2019-02-15 | 2023-08-15 | Regents Of The University Of Minnesota | Methods to identify modulators of tau protein structure |
CN110243792A (en) * | 2019-06-11 | 2019-09-17 | 山东师范大学 | A kind of fluorescence chemical sensor and its detection method and application based on quantum dot and tetrahedron DNA structure |
US11656221B2 (en) | 2019-06-11 | 2023-05-23 | Regents Of The University Of Minnesota | Methods to identify modulators of actin-binding proteins |
CA3170833A1 (en) | 2020-02-21 | 2021-08-26 | Harpoon Therapeutics, Inc. | Flt3 binding proteins and methods of use |
CN116087069B (en) * | 2023-04-10 | 2023-08-08 | 苏州药明康德新药开发有限公司 | Method for detecting histone methylation and acetylation modification level of specific cell population based on flow cytometry |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI102922B (en) * | 1996-06-28 | 1999-03-15 | Valtion Teknillinen | Fluorescence based immunoassay method |
JP2001519525A (en) * | 1997-10-07 | 2001-10-23 | メルク エンド カムパニー インコーポレーテッド | Assay for nuclear receptor ligands using FRET |
EP1116036B1 (en) * | 1998-09-18 | 2004-08-11 | Massachusetts Institute Of Technology | Water-soluble fluorescent semiconductor nanocrystals |
US6140054A (en) * | 1998-09-30 | 2000-10-31 | University Of Utah Research Foundation | Multiplex genotyping using fluorescent hybridization probes |
GB9926336D0 (en) * | 1999-11-05 | 2000-01-12 | Isis Innovation | Universal flourescent sensors |
JP2001204497A (en) * | 2000-01-20 | 2001-07-31 | Japan Science & Technology Corp | Method for detecting dna by dna hybridization method by utilizing transfer of fluorescence resonance energy |
AU2002230419A1 (en) * | 2000-11-08 | 2002-05-21 | Science And Technology Corporation @Unm | Fluorescence and fret based assays for biomolecules on beads |
DE60207700T2 (en) | 2001-04-23 | 2006-08-10 | Eiken Kagaku K.K. | ANALYSIS PROCEDURE WITH INTERMOLECULAR INTERACTION OF A REPORTER (MARKER) |
EP1409982A4 (en) * | 2001-06-14 | 2006-05-24 | Anadys Pharmaceuticals Inc | Methods of screening for ligands of target molecules |
JP4537053B2 (en) * | 2001-06-25 | 2010-09-01 | ジョージア テック リサーチ コーポレーション | Double resonance energy transfer nucleic acid probe |
US20030228603A1 (en) * | 2002-04-05 | 2003-12-11 | Cload Sharon T. | Compositions selective for caffeine or aspartame and methods of using same |
WO2004042404A1 (en) | 2002-11-07 | 2004-05-21 | Erasmus Universiteit Rotterdam | Fret probes and methods for detecting interacting molecules |
-
2003
- 2003-11-06 WO PCT/NL2003/000777 patent/WO2004042404A1/en active Application Filing
- 2003-11-06 DE DE60320828T patent/DE60320828D1/en not_active Expired - Lifetime
- 2003-11-06 NZ NZ540219A patent/NZ540219A/en unknown
- 2003-11-06 ES ES03776064T patent/ES2306900T3/en not_active Expired - Lifetime
- 2003-11-06 CN CNA2003801083656A patent/CN1735808A/en active Pending
- 2003-11-06 JP JP2004549718A patent/JP4511363B2/en not_active Expired - Fee Related
- 2003-11-06 AT AT03776064T patent/ATE394677T1/en not_active IP Right Cessation
- 2003-11-06 CA CA2505515A patent/CA2505515C/en not_active Expired - Fee Related
- 2003-11-06 AU AU2003283860A patent/AU2003283860B2/en not_active Ceased
- 2003-11-06 EP EP03776064A patent/EP1561114B1/en not_active Expired - Lifetime
-
2005
- 2005-05-05 US US11/122,776 patent/US7413862B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
AU2003283860B2 (en) | 2009-09-17 |
EP1561114A1 (en) | 2005-08-10 |
ES2306900T3 (en) | 2008-11-16 |
NZ540219A (en) | 2008-08-29 |
DE60320828D1 (en) | 2008-06-19 |
WO2004042404A1 (en) | 2004-05-21 |
ATE394677T1 (en) | 2008-05-15 |
US20050260660A1 (en) | 2005-11-24 |
JP4511363B2 (en) | 2010-07-28 |
CA2505515A1 (en) | 2004-05-21 |
CN1735808A (en) | 2006-02-15 |
AU2003283860A1 (en) | 2004-06-07 |
JP2006505775A (en) | 2006-02-16 |
CA2505515C (en) | 2013-08-27 |
US7413862B2 (en) | 2008-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1561114B1 (en) | Fret probes and methods for detecting interacting molecules | |
AU2003283860A2 (en) | Fret probes and methods for detecting interacting molecules | |
US7575874B2 (en) | Method and probes for the detection of a tumor specific fusion protein | |
US6492125B2 (en) | Method to assess library X library interactions | |
Thompson et al. | Recent advances in fluorescence correlation spectroscopy | |
US20120003632A1 (en) | fret-probes and use thereof | |
AU771927B2 (en) | Multihued labels | |
CN107924473A (en) | The super-resolution imaging of protein protein interaction | |
Poluri et al. | Experimental methods for determination of protein–protein interactions | |
CN114555125A (en) | Polynucleotide-linked bioconjugates and methods of making and using the same | |
US20050124008A1 (en) | Homogeneous competition assays | |
Sharma et al. | 9.1 PROTEIN AS CRUCIAL BIOMOLECULES AND ITS LABELLING |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050606 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20060725 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: LANGUAGE OF EP DOCUMENT: FRENCH |
|
REF | Corresponds to: |
Ref document number: 60320828 Country of ref document: DE Date of ref document: 20080619 Kind code of ref document: P |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080507 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080507 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080507 |
|
NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2306900 Country of ref document: ES Kind code of ref document: T3 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080507 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080807 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080507 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080507 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20081007 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080507 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080507 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080507 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20090210 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080507 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080807 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20081130 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20081106 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20081130 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20081130 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20081106 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080507 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20081108 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080507 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080808 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20151124 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20151126 Year of fee payment: 13 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 14 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161106 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 15 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161107 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20181121 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20201120 Year of fee payment: 18 Ref country code: FR Payment date: 20201120 Year of fee payment: 18 Ref country code: DE Payment date: 20201119 Year of fee payment: 18 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 60320828 Country of ref document: DE |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20211106 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211106 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220601 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211130 |